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Abstract
Trophoblast differentiation and invasion is essential for normal implantation and
establishment of the maternal-fetal interface, which allows for proper nutrient exchange
and support of the fetus. For this to occur, cytotrophoblasts must undergo an epithelial
to mesenchymal transition and differentiate into migratory and invasive extravillous
trophoblasts (EVTs) that invade the maternal decidua and myometrium. Trophoblast
differentiation, migration and invasion is highly regulated by a complex network of
signaling pathways, adhesion molecules and transcription factors and is important for
the remodeling of maternal spiral arteries from low flow, high resistance to high flow, low
resistance vessels to allow optimal perfusion of the fetus and the placenta.
Cytotrophoblasts also differentiate into syncytiotrophoblasts which form the outer layer
of the placenta and are important for fetal-maternal gas exchange.
The chromosome 19 miRNA cluster (C19MC) and the RNA binding protein Lin28
are highly expressed in embryonic stem cells, the placenta and certain cancers. C19MC
is the largest human miRNA cluster that spans over 100 kb. It is primate specific and
contains 46 miRNA genes flanked by Alu elements. C19MC is regulated by genomic
imprinting. The expression of C19MC often correlates closely with the RNA binding
protein LIN28. LIN28 was originally discovered as a regulator of developmental timing
due to its inhibitory effects on the expression of the let-7 miRNA family. Two paralogs,
LIN28A and LIN28B exist in vertebrates, which were shown to regulate thousands of
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mRNAs transcripts involved in cellular processes including stem-cell self-renewal, cell
differentiation, proliferation, migration, and cellular metabolism.
The role of C19MC miRNAs in the regulation of EMT, trophoblast differentiation
and somatic cell reprogramming has not been fully determined. In this study, we
hypothesized that hypoxic conditions during implantation and placentation downregulate
C19MC expression, which in turn induces EMT genes, resulting in trophoblast
differentiation toward EVTs.

In this study we found that C19MC is highly expressed in villous cytotrophoblasts
but not in differentiated EVTs or decidual cells in human first trimester placenta tissues.
CRISPR/Cas9 mediated overexpression of C19MC inhibited the expression of EMT
markers SNAI1, CDH2, TWIST1 and SERPINE1, induced the expression of
reprogramming factors OCT4 and FGF4, and enhanced the reprogramming of human
fibroblasts to iPSCs. Importantly, hypoxic conditions decreased the expression of
C19MC and increased the expression of EMT markers in iPSCs. This study
demonstrates that overexpression of C19MC induces epithelial cell phenotype and
enhances cell reprogramming. Furthermore, exposure to hypoxic conditions induces
EMT and trophoblast differentiation at least in part by inhibiting C19MC and
reprogramming factors.

Recently, C19MC was reported to be highly expressed in infantile hemangiomas
(IH). IH are benign tumors of infancy characterized by rapid growth phase followed by
spontaneous involution. During the proliferative phase, immature glucose transporter-1

xiv

(GLUT1) positive endothelial cells form highly disorganized blood vessels. IH lesions
also highly express C19MC and the stem cell reprogramming factors Oct4, Sox2,
Nanog and Myc. When GLUT1 and C19MC expressing endothelial cells isolated from
proliferating IH are grown in culture, they lose expression of both GLUT1 and C19MC
and undergo an endothelial to mesenchymal transition. Propranolol, a beta-adrenergic
receptor blocker, has been shown to trigger early IH tumor involution and has
subsequently become first line treatment for IH patients. The levels of circulating
C19MC correlated with tumor phase and with propranolol treatment. Some studies have
shown considerable similarities between IH and placental transcriptomes suggesting a
placental origin for proliferating endothelial cells in IH. On the other hand, other studies
have proposed that IH originate from Hemangioma stem cells. This theory is supported
by studies which show that human CD133+ hemangioma stem cells recapitulate the
entire IH life cycle when implanted subcutaneously into immunocompromised mice.
The expression of C19MC miRNAs have been strongly correlated with the
expression of the RNA binding protein LIN28. Although LIN28/let-7 axis plays a central
role in the regulation of stem cell self-renewal and tumorigenesis, the role of LIN28B/let7 signaling in IH pathogenesis has not yet been elucidated. We hypothesized that the
LIN28/let-7 signaling pathway is dysregulated in IH and is modulated by propranolol
treatment during IH involution. We found that LIN28B is highly expressed in proliferative
IH compared to involuted IH and propranolol treated IH. The increase in LIN28B
correlated with C19MC expressed and inversely correlated with let-7. Overexpression of
LIN28B in HEK293 cells increased the expression of miR-516b, a C19MC miRNA.
Moreover, iPSCs treated with propranolol decreased the expression of C19MC miRNAs

xv

and LIN28B and increased the expression of let-7. Importantly, propranolol treatment
decreased iPSC proliferation and increased the expression of EMT markers. These
results describe for the first time, the role of the LIN28/let-7 switch in IH pathogenesis
and identifies a novel mechanism by which propranolol induces IH involution.
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Chapter 1
Placental Development
Establishment of the trophectoderm and inner cell mass
Successful fertilization results in the formation of the zygote, a diploid cell formed
from the fusion of two haploid gametes. The zygote is totipotent and can give rise to the
entire embryo and the extra embryonic tissue. It utilizes a stockpile of RNAs and
proteins from the oocyte to drive their initial development. At the 2-cell stage, a
mechanical separation of the blastomeres occurs. In humans, at the 4- to 8-cell stage,
series of genetic and epigenetic reprogramming and identical cellular divisions results in
a major wave of embryonic genome activation1. Once they reach the compacted 8-cell
stage, the cells become polarized. Consequently, symmetrical and asymmetrical
divisions occur during the transition from 8-cell to 16-cell stage, when the first cell fate
determination of embryogenesis begins, known as the blastocyst stage. During this
process, the outer cells remain polarized and develop into the bipotent trophectoderm
(TE), while the inner cells lose polarity and develop into the pluripotent inner cell mass
(ICM) 2. TE differentiate into trophoblasts from which the placenta is derived whereas
the ICM generates the three germ layers, mesoderm, endoderm and ectoderm that
ultimately gives rise to the fetus.
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During embryonic genome activation, a dramatic reprogramming of gene
expression occurs. The master transcriptional regulator Oct4, is highly expressed in the
oocytes, blastomeres and in the ICM, and controls pluripotent cell self-renewal.
Targeting OCT4 in human zygotes using an inducible human embryonic stem (ES) cellbased CRISPR–Cas9 system resulted in a poorly formed ICM and subsequent embryo
collapse3. In vitro, Oct4 knockout embryos develop to the blastocyst stage and
extraembryonic TE lineage but were unable to form pluripotent ICM cells4, 5. Sox-2, is
another transcription factor required for ICM development. Together with Oct4 it binds to
a powerful enhancer of Fgf4, and induces its expression 6, 7. This regulation is important
as Fgf4 is a key signaling factor that drives cellular specification within the ICM and also
provides paracrine signaling that stimulates growth and proliferation of the developing
TE4. Loss of Sox-2 impairs Oct4 binding to its target genes and leads to developmental
defects8, 9. Nanog is another transcription factor that is critical for the development of the
cells of the ICM. Nanog deficient embryos are unable to generate epiblast and only
produce parietal endoderm-like cells 11. In the absence of Nanog, pluripotency cannot
be established and the cells of the ICM are unable to progress beyond an intermediate
state10, 11. Therefore, these embryonic transcriptional factors are important parts of a
regulatory circuit that coordinate the expression of many downstream genes required
during normal development.
The development of the TE is contingent on an entirely different set of
transcription factors such as Cdx2 and Tead4. Cdx2 is expressed in the TE and
reinforces cell specification to the TE layer. Homozygous deletion of the Cdx2 gene
leads to death of the embryo around the time of implantation. Cdx2 mutants are able to
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form the blastocoel but cannot maintain epithelial integrity and show a failure of
implantation12. Cdx2 is also important for downregulating the expression of Oct4 and
Nanog and maintaining the spatial restriction of these proteins12. Furthermore, Cdx2
promotes symmetrical divisions which allocates more cells to the TE and reinforces cell
polarity by upregulating aPKC13. Tead4 is also important for TE formation. Tead4
knockout embryos do not produce trophoblast stem cells or TE and this knockout
results in a preimplantation lethal phenotype 14. These embryos did not express TE
specific genes such as Cdx2 but expressed genes that are specific to the ICM such as
Oct4, indicating that Tead4 is upstream of Cdx2 15.
Recently, LIN28 which belongs to a class of RNA binding proteins, has also been
shown to be important for development of the ICM and TE. LIN28 is highly expressed in
embryonic stem cells (ESC) and early embryonic tissue, but declines upon
development16, 1718. Mice embryos, highly express LIN28 in both ICM and TE cells, in all
three germ layers and the extraembryonic layer17, 19. In addition, LIN28 depletion from
mouse zygotes prevents the transition from the 2-cell to 4- cell stage indicating that
LIN28 plays an important role in early embryo development19.
The placenta
The placenta is a highly complex organ that primarily serves as the interface
between mother and fetus. It’s importance in fetal development cannot be overstated as
it performs a variety of essential functions including digestive, respiratory, excretory,
immune and endocrine systems. The placenta undergoes major structural changes
between the first trimester during organogenesis and the remainder of pregnancy 20.
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Trophoblast differentiation in early pregnancy
Trophoblasts are the first cells to differentiate from the fertilized egg during the
first stage of pregnancy. They are derived from the outer layer of the blastocyst which
develops into a large portion of the placenta and primarily provide nutrients to the
embryo. Trophoblasts adhere to the uterus and initiate implantation and so are very
important for initiation and maintenance of a successful pregnancy. Trophoblasts
differentiate into two major lineages: syncytiotrophoblasts (STs) and extravillous
trophoblasts (EVTs), while maintaining a stem population of villous cytotrophoblasts
(CTs) throughout the course of pregnancy.
STs are specialized epithelial cells that cover the chorionic villi and are in direct
contact with maternal blood. They are directly responsible for maternal-fetal gas
exchange and nutrient transport during pregnancy. They also perform endocrine
functions including the production of growth factors and hormones, protect the fetus
from infections, xenobiotics and drugs and regulate fetal programming20, 21.
EVTs are derived from proliferating CTs in the placental cell columns and
comprise of endovascular and interstitial invasive trophoblasts. The interstitial
trophoblasts migrate to and invade the maternal uterine tissue to anchor the placenta to
the uterus. The endovascular trophoblasts on the other hand, migrate to the maternal
uterine spiral arteries and facilitate their remodeling into high-flow, low-resistance
vessels that ease placental perfusion and nutrient uptake. This conversion of maternal
spiral arteries ensures sufficient blood flow and must occur by the end of the first
trimester of a successful pregnancy.
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During the first stages of pregnancy the placenta develops in a relatively hypoxic
environment. The partial pressure of oxygen in the placenta is significantly lower than in
the endometrium between 8 and 10 weeks. During this time, EVT plugs block the
maternal spiral arteries and prevent maternal blood flow from entering the intervillous
space. This indicates that placental and fetal development in the early stages largely
takes place in hypoxia. At the end of the first trimester, hypoxia in the placental bed is
abated by the displacement of trophoblast plugs which exposes the placenta to
maternal blood flow and establishes the maternal-placenta circulation22.
Deficiencies in trophoblast migration and invasion result in several diseases of
pregnancy such as preeclampsia or placenta accreta 20, 21 23. EVT invasion requires
cellular transition from an epithelial phenotype to a mesenchymal phenotype which is
essential for efficient implantation and placentation.
Epithelial to mesenchymal transition (EMT)
EMT refers to the process by which polarized epithelial cells undergo
biochemical changes to gain mesenchymal cell characteristics which include enhanced
migratory capacity, invasiveness, increased production of extra cellular matrix (ECM)
components and greater resistance to apoptosis24. A total EMT is characterized by the
degradation of the underlying basement membrane and the migration of the resulting
mesenchymal cell to a more distant site24.
EMTs have been classified into three distinct subtypes. Type 1 EMTs are
associated with organ development, implantation and embryo formation. It is highly
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essential for the movement of cells in the embryos during development as cells
differentiate and move between epithelial and mesenchymal states24, 25. Type 2 EMTs
are associated with fibrosis and wound healing and begin as part of a repair mechanism
that generates fibroblasts and related cells following trauma or injury. These EMTs are
associated with inflammation and are discontinued as soon as inflammation is abated.
Continued inflammation elicits a continuous EMT response and can lead to tissue
fibrosis and organ damage. Type 3 EMTs are associated with cancer cells which gain
the ability to metastasize to and invade secondary tumor sites. Type 3 EMTs in cancer
cells may be partial or complete with cells often maintaining both epithelial and
mesenchymal characteristics. Although EMTs can be classified into these 3 distinct
types, they are all governed by a common set of transcription factors that regulate the
expression of downstream genes and miRNAs that results in the production of
enzymes that degrade the ECM and enable detachment24 (Figure 1).
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Figure 1. Epithelial to mesenchymal transition (EMT).
EMT involves the transition between polarized epithelial cells to migratory mesenchymal
cells that secret ECM components. Common epithelial and mesenchymal cell markers
are listed below each cell type. EMT can also generate cells which display an
intermediate phenotype defined by the possession of both epithelial and mesenchymal
cell properties.
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Molecular regulation of EMT during early placental development
EMT is regulated by well-orchestrated series of molecular processes that include
signal induction and transduction within the cell through key transcription factors. Many
EMT inducers have been identified to date including hypoxia and the transcription
factors SNAIL, SLUG and TWIST. The TGFβ and Wnt signaling pathways also regulate
key transcription factors that induce phenotypic changes characteristic of EMT26-28.
The transcriptional repressors SNAIL and SLUG, members of the SNAIL family
of zinc-finger proteins play important roles in EMT. SNAIL has been shown to be a
potent inducer of EMT primarily through the repression of the epithelial marker ECadherin29-31. SNAIL binds directly to E-boxes in the E-cadherin promoter to repress its
expression31. SNAIL has also been shown to directly repress the expression of the tight
junction adhesion claudin and occuldin genes important for the maintenance of
epithelial cell architecture32. In villous explant cultures, low oxygen conditions increased
the expression of SNAIL which led to a decrease in E-cadherin, increase in integrin α5
and a significant increase in EVT invasion33. The increase in expression of SNAIL
expression in low oxygen condition was due to direct binding of HIF-1α to its
promoter34. These findings suggest that low-oxygen tensions in early pregnancy lead to
the upregulation of SNAIL, which causes a decrease in the expression of epithelial
adhesion and junctional proteins thus promoting EMT and an increase in EVT cell
migration and invasion. Like SNAIL, SLUG also directly represses the expression of Ecadherin in epithelial cells and breast cancer cells and induces EMT35,
36

.Choriocarcinoma-derived JEG3 cells treated with cyclosporin A, an
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immunosuppressive agent, showed increased SLUG expression, decreased Ecadherin expression and increased invasiveness37. These studies indicate that SLUG
and SNAIL likely promote EMT through the same molecular mechanisms.
SNAIL and SLUG also activate a key regulator of EMT, the Wnt/ β-catenin
signaling pathway, which play important roles in every aspect of embryonic
development, stem cell maintenance, EVT differentiation and invasion cell
differentiation38. SNAIL and SLUG initiate EMT by promoting the formation of the βcatenin/TCF complex, which increases the binding to the TGFβ3 promoter to increase
its transcription39. Expression of TCF3/4 is significantly increased in invading
trophoblasts and treatment of primary cytotrophoblasts with Wnt3A significantly
increased trophoblast migration and invasion through matrigel26. Furthermore, silencing
of TCF-4 in primary cytotrophoblasts caused a decrease in the expression of EMT
markers SNAIL, integrin α1 and integrin α540.
The multifunctional cytokine, transforming growth factor β superfamily (TGFβ),
has been shown to have contradictory effects on cell behavior41. Although TGFβ can act
as a tumor suppressor during the early stages of cancer development, TGFβ can also
function as a potent inducer of EMT42. TGFβ activates the transcription factors Smad2
and Smad3 which bind Smad4 and together promote the transcription of SNAIL and
initiation of EMT43, 44.
TWIST is another transcriptional regulator of EMT. TWIST plays an essential role
in the regulation of embryonic morphogenesis and tumor metastasis. Increasing the
expression of TWIST in epithelial cells led to a loss of E-cadherin, cell-cell adhesion and
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the activation of mesenchymal cell markers vimentin, fibronectin, smooth muscle actin
and N-cadherin45. TWIST is highly expressed in EVTs and siRNA mediated silencing of
the TWIST gene resulted in a decrease in N-cadherin and significantly reduced the
invasive capacity of the EVT cell line HTR8/SVneo46. In addition, TWIST modulates the
expression of E-cadherin and regulates syncytium formation in choriocarcinoma-derived
BeWo cells47.
Hypoxia is also a potent inducer of EMT. Studies have shown that hypoxia
promotes EMT in a different variety of cancers and cell types48. Hypoxia induced EMT is
mediated by the activation of the Hypoxia Inducible Factor (HIF) pathway. Activation of
the transcription factor HIF-1α leads to the upregulation of EMT transcription factors
such as SNAIL, SLUG and TWIST in different cancers49-51. Furthermore, hypoxic
conditions activate EMT signaling pathways including TGFβ and Wnt signaling which
further promote EMT48. These studies indicate that hypoxia induces EMT by
simultaneously activating multiple transcription factors and signal transduction
pathways.
During normal placental development, EVTs lose their organized epithelial
phenotype and transition into a more migratory and invasive mesenchymal phenotype
that facilitates the deep infiltration of the maternal decidua and blood vessels.
Furthermore, some of these invasive cells have the capacity to terminally differentiate
into giant cells of the placental bed and the myometrium52. Although the regulatory
networks underlying EMT in trophoblasts are not very well understood, numerous
similarities can be found in the extensive studies of EMT in cancer27. Interestingly, EVTs
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share many phenotypic characteristics with cancer cells including rapid proliferation,
migration, ability to invade surrounding tissues, and resistance to the innate immune
system53, 54. Studies have shown that trophoblasts and cancer cells express many of the
same growth factors, proto-oncogenes, enzymes, hormones and adhesion molecules
that are likely responsible for the similar characteristics of both cell types. Furthermore,
activation of the phosphatidylinositol 3'-kinase (PI3K)/AKT signaling pathway has been
shown to be central to many of the mechanisms through which trophoblasts and cancer
cells achieve their proliferative, migrative and invasive properties53. A major difference
between both cell types is that EVT invasion is restricted to the decidua and the first
third of the myometrium suggesting tight spatio-temporal control of trophoblast behavior
by the uterine microenvironment55. Furthermore, EVT ability to undergo terminal
differentiation significantly restricts their tumorigenic potential. Importantly, disruption of
trophoblast invasion or migration can lead to serious consequences during pregnancy.
For example, shallow invasion is a defining feature of preeclampsia and fetal growth
restriction, whereas abnormally deep invasion is characteristic of placenta accreta and
choriocarcinomas which are associated with uncontrolled EVT invasion56, 57.
Regulation of trophoblast migration and invasion
Trophoblast migration and invasion into the maternal uterine tissues is essential
during pregnancy and fetal development. Invasive trophoblasts have numerous abilities
including hormone and cytokine production and communication with maternal immune
cells58. In addition, invasive trophoblasts exhibit high plasticity which enables them to
anchor the placenta to maternal tissues, replace endothelial cells of the maternal spiral
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arteries and modulate angiogenesis and lymphangiogenesis. Deficiencies in trophoblast
migration and invasion can lead to potentially serious complications during gestation
such as early miscarriages, preeclampsia, intrauterine growth restriction, placenta
accreta, premature birth, and maternal or fetal death. Studies aimed at identifying
molecular mechanisms that control this process have identified several molecular
pathways that control trophoblast migration and invasion under physiological conditions
and in disease59-61.
Regulation of trophoblast invasion in humans is tightly controlled by cytokines
and growth factors by the activation of the phosphatidylinositol-3-kinase/serinethreonine (PI3K/Akt) signaling pathways62. Disruption of PI3K/AKT using inhibitors
altered the invasive trophoblast gene expression profile and impaired trophoblast
invasion. This regulation has been shown to be mediated by the nuclear protein FOSL1,
a downstream effector of the PI3K/AKT signaling pathway63. Knockdown of FOSL1
disrupts the invasive trophoblast gene expression phenotype, abolishes trophoblast
invasion, and is associated with the inhibition of matrix metalloproteinase protein
(MMP1, MMP3 and MMP10) expression63. Interestingly, secretion of PI3K/AKT
signaling activators is not exclusive to trophoblast. The decidua, uterine macrophages
and uterine natural killer cells also secrete PI3K/AKT activators suggesting a complex
network of activators and mediators that regulate trophoblast invasiveness64.
CTs in cell columns show decreased E-cadherin and high VE-(endothelial)
cadherin, platelet-endothelial adhesion molecule-1 (PECAM-1), vascular endothelial
adhesion molecule-1 (VCAM-1), and alpha-4-integrins65. Some studies suggest that
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defective trophoblastic invasion of maternal spiral arteries result from inadequate EMT
and vascular adhesion molecule expression. Invading trophoblasts from preeclamptic
placentas did not sufficiently express integrin, cadherin and Ig superfamilies suggesting
an association between preeclampsia and CT failure to assume the appropriate
vascular phenotype65, 66. However, other studies have reported conflicting results67, 68.
During implantation, CT differentiation into EVTs is also accompanied by a change in
the expression of adhesion molecules at the cell surface. Depending on their location,
EVTs express different members of the integrin family which determine their interaction
with collagens and laminin69. These changes are associated with the EMT exhibited by
EVTs58.
The TGFβ signaling pathway is also an important regulator of trophoblast
invasion. Of the 3 TGFβ isoforms that exist, TGFβ1 and TGFβ2 are thought to be the
most important at the maternal-fetal interface. TGFβ2 but not TGFβ1 is expressed by
EVTs within the placental bed while extracellular TGFβ1 and cytoplasmic TGFβ2 were
detected in the decidual layer70. TGFβ1 has been shown to inhibit cell invasion and
promote intercellular adhesion71. Moreover, another study showed that TGFβ1
treatment of the EVT cell line HTR8/SVneo decreased cell invasion and decreased the
expression of VE-cadherin. This study also showed that the TGFβ1 induced decrease in
VE-cadherin expression and subsequent decrease in cell invasion is mediated by
SNAIL72. These findings suggest that TGFβ plays a role in regulating the extent of
trophoblast invasion of the maternal endometrium73.

13

Growth factors and cytokines have also been shown to directly influence human
trophoblast behavior. Growth factors, such as EGF, VEGF, PDGF, CSF-1, IGF-1 and
IGF-2, act at the fetal-maternal interface to stimulate trophoblast cell proliferation,
adhesion and invasion74-76. While other inhibitory proteins, such as the TGFβ family,
endostatin, TNFα, INFγ and fetuin-A, inhibited trophoblast invasion and migration in
vitro77-80. Cytokines such as CXCL16, CXCR6, CXCL6 and CXCL14 have also been
reported to regulate trophoblast migration and invasion81-83. Taken together, trophoblast
invasion and migration are a tightly regulated process that is governed by a complex
regulatory network which when dysregulated, can lead to pathological outcomes in
pregnancy.
Diseases related to impaired placentation
Preeclampsia is a disease typically diagnosed after 20 weeks of pregnancy.
Clinical characteristics of preeclampsia include severe hypertension (systolic blood
pressure above 140 mmHg and diastolic blood pressure above 90 mmHg), proteinuria,
maternal edema and seizures. This disease is associated with shallow trophoblast
invasion and impaired conversion of maternal spiral arteries20. Insufficient maternal
artery remodeling compromises the blood flow to maternal-fetal interface and leads to
hypoxic conditions for the developing fetus. A study proposed that the insufficient
invasion and impaired spiral artery remodeling in preeclampsia is caused by the failure
of invading CTs to mimic a vascular phenotype66. This study showed that invading CTs
in placenta biopsy specimen from preeclampsia do not properly express many adhesion
molecules including integrins, cadherins and Ig family members66. Other studies
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showed that macrophages reside in excess in the placental bed from preeclamptic
pregnancies and can limit trophoblast invasion through apoptosis84, 85. Metabolic
diseases such as diabetes and thyroid disorders can also adversely affect trophoblast
invasion and predispose mothers to preeclampsia. A study showed that excess glucose
reduced angiogenesis and migration and increased inflammation in first trimester
trophoblast cells86. A study in rats showed that maternal hypothyroidism reduced
trophoblast migration and invasion and altered the immune profile in the placenta87.
These studies suggest that deficiencies in a number of mechanisms that control
trophoblast migration and invasion can lead to the development of preeclampsia during
pregnancy.
Excessive trophoblastic invasion on the other hand, can also lead to placental
dysfunction. Placenta creta (accreta, increta and percreta) develop when the anchoring
villi and EVTs invade beyond the initial third of the myometrium to reach the perimetrium
or extra-uterine tissues and organs23, 58. Classification as accreta, increta or percreta
depends on the extent of invasion, with placenta percreta being the most severe form of
the disease23. This condition is associated with impaired decidual formation which
permits trophoblast hyper invasion into the myometrium60. Despite the increased
invasion, placenta creta is still associated with incomplete vascular remodeling of
maternal spiral arteries60. Placenta creta can cause heavy bleeding during pregnancy
and childbirth.
Finally, a study of placental beds from late miscarriages showed that late
sporadic miscarriage is associated with decreased endovascular and interstitial
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trophoblast populations, decreased trophoblast invasion and impaired remodeling of
maternal spiral arteries88. Miscarriages can occur at the beginning and end of
pregnancy and more studies are needed to determine the underlying causes of this
condition.
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Chapter 2
The Chromosome 19 MicroRNA Cluster
MicroRNAs (miRNAs) are short 22 nucleotide long RNAs that posttranscriptionally regulate gene expression by degrading or inhibiting translation of their
target mRNAs. They perform their gene regulatory function by base pairing between the
miRNA seed sequence (nucleotide position 2-8 of the mature miRNA) and
complementary sequences in the 3’ untranslated regions (UTRs) of their targets89, 90.
miRNAs have been shown to regulate many developmental and physiological
processes including embryonic stem cell differentiation, cell proliferation, migration,
invasion and stem cell reprogramming89, 91.
The chromosome 19 miRNA cluster (C19MC) is the largest miRNA cluster
discovered in the human genome. It is located in an imprinted region on chromosome
19 and its entire genomic region is conserved in but not beyond primates92, 93. The
C19MC cluster is composed of 49 miRNA precursors, interspersed with Alu repeats,
which generate 53 unique mature miRNAs92. These miRNAs are highly similar, with
many of them sharing the same seed sequence, indicating that they regulate common
sets of genes94-96. In fact, common seed comparison analysis showed that C19MC
miRNAs likely regulate genes involved in embryonic development and tumorigenesis92.
C19MC is physiologically expressed in ESCs and the placenta97-99. DNA
methylation profiling of the C19MC locus identified a differentially methylated CpG rich
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promoter region approximately 17 kb upstream of the first C19MC miRNA (Figure 2).
C19MC miRNAs are located at the intronic regions of a large RNA polymerase II noncoding transcript and are processed by the DGCR8-Drosha microprocessor complex93.
In addition, chromatin immunoprecipitation and in vitro transcription assays showed that
Pol III is also associated with and transcribes some miRNAs of the C19MC100.

C19MC in stem cells and cell reprogramming
C19MC is expressed in ESCs and is part of a unique ESC miRNA signature that
includes miR-302, miR-17, miR-106 and miR-371 clusters99, 101. Bioinformatics analysis
showed that 16 of the C19MC miRNAs share the same “AAGUGC” seed sequence with
members of the miR-302 cluster that target genes involved in signaling pathways
related to the maintenance of stemness99, 102.
Recently, a study showed that the miR-302/367 cluster rapidly and efficiently
reprogram mouse and human somatic cells to an iPSCs without the use of exogenous
reprogramming factors103. Moreover, combination of stem cell enriched miRNAs with
the reprogramming factors increased the efficiency of somatic cell reprogramming to
iPSCs91. Similarly, miR-524, a C19MC miRNA, was also shown to increase the
efficiency of reprogramming when co-expressed with reprogramming factors104. This
study showed that miR-524 promotes cell reprograming by increasing cell proliferation,
decreasing apoptosis, promoting MET and increasing the expression of pluripotency
genes.
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C19MC in the placenta
C19MC miRNAs are highly expressed in the placenta and have been reported to
play important roles in placental development. Laser-capture microdissection
experiments in first trimester and term human placentas showed that C19MC miRNAs
are abundantly expressed in villous trophoblasts (VT) but are reduced in invasive
EVTs105. To investigate the role of C19MC in trophoblast invasion, bacterial artificial
chromosome (BAC) was employed to overexpress C19MC miRNAs in the EVT-derived
cell line HTR8/SVneo. This study showed that overexpression of C19MC inhibited cell
migration105. Furthermore, ectopic expression of several individual C19MC miRNAs also
inhibited the migration and invasion of EVTs106-108. MiRNAs of the miR-515 family, that
belong to C19MC, were significantly down-regulated during human ST differentiation.
Importantly, in placentas from women with preeclampsia, these miRNA were
significantly up-regulated109. Therefore, C19MC plays an important role the regulation of
trophoblast differentiation and optimal trophoblast migration and invasion essential for
proper implantation.
Another important role of C19MC miRNAs in the placenta is the protection
against viral infections. Primary human trophoblasts (PHT) which express high levels of
C19MC, have been shown to be resistant to infection by a number of viruses including
coxsackievirus B3, poliovirus, vesicular stomatitis virus (VSV), vaccinia virus, human
cytomegalovirus and herpes simplex virus110. Furthermore, PHT derived exosomes
were sufficient to confer viral resistance to VSV infection in recipient cells110. Further
confirming these results, exposure to PHT conditioned medium, stable transfection of a
C19MC BAC or miRNA mimics into non-trophoblastic cells sufficiently attenuated viral
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infection110 111. C19MC has been shown to confer viral resistance primarily through the
induction of autophagy in recipient cells, since inhibition of autophagy ablates the
antiviral response110, 112.
Altered expression of C19MC miRNAs has been reported in preeclampsia.
Numerous studies reported increase in C19MC miRNAs in placentas from severe
preeclampsia compared to placentas from normal pregnancies106, 108, 109, 113, 114. In
addition, circulating C19MC miRNAs are increased in plasma from preeclamptic
patients compared to plasma from patients with normal pregnancies indicating that they
can be used as non-invasive diagnostic biomarkers for the disease114, 115. Furthermore,
expression of the C19MC miRNA, miR-517a, in first trimester plasma samples showed
high predictive value for identifying patients that subsequently developed
preeclampsia116.

C19MC in benign tumors and cancers
In addition to its physiological expression in stem cells and the placenta, C19MC
is also found in few benign tumors and cancers. Chromosomal abnormalities at 19q13.4
were reported in mesenchymal liver hamartoma which is a rare benign tumor of
childhood117 and in a subgroup of benign thyroid adenomas118. C19MC miRNAs have
also been reported to be overexpressed in another benign tumor of infancy, infantile
hemangioma (IH) 119. In IH, but not other vascular malformations, C19MC miRNAs were
localized to the endothelial cells and circulating C19MC miRNAs were detected in the
plasma of IH patients. Therefore, circulating C19MC miRNAs may be serve as a
noninvasive tool to diagnose IH and monitor treatment response119.
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Amplification of the C19MC was first reported in central nervous system primitive
ectodermal tumors (CNS-PNETs) including the deadly embryonic tumors with
multilayered rosettes (ETMRs), embryonal tumors with abundant neuropil and true
rosettes (ETANTR), medulloepitheliomas, ependymoblastomas, and PNETs with
atypical histologic features120 121-123. Integrated genetic and epigenetic analyses of
ETMR samples found that the amplification is driven by the fusion of the C19MC
amplicon to the TTYH1 gene, which encodes a chloride channel that is highly
expressed in neural tissue 121. Importantly, amplification in C19MC correlated closely
with upregulation of the RNA-binding pluripotency gene, LIN28 in CNS-PNETs124.
However, the relationship between C19MC and LIN28 remain to be completely
elucidated.
Studies have also shown that C19MC is highly expressed in triple negative
breast cancers and hepatocellular carcinomas125-127. Furthermore, C19MC miRNAs are
expressed in parathyroid tumors and correlated with aggressive tumor behavior128.
Therefore, C19MC miRNAs can be amplified by chromosomal rearrangements and
contribute to the pathogenesis of both benign and malignant neoplasms.
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Figure 2. Simplified schematic representation of the C19MC locus and its
surrounding genes on chr19q13
Open and closed lollipops indicate unmethylated and methylated CpG regions
respectively and represent the differentially methylated region located approximately
17kb upstream of C19MC. Arrows indicate transcription direction.
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Chapter 3
LIN28 in Stem Cells and the Placenta
The RNA binding protein LIN28
LIN28 is an important RNA-binding protein that is highly expressed in embryonic
stem cells. It is a master regulator of development, differentiation and metabolism129.
Vertebrates have two LIN28 paralogs, lin-28A and lin-28B, both containing a unique
RNA-binding domain; the N-terminal cold shock domain (CSD) and a pair of cysteine
cysteine histidine cysteine-type zinc fingers that form a zinc knuckle domain (ZKD) at
the C-terminal. The human LIN28A and LIN28B share approximately 73% sequence
homology130, however they differ in a few important ways130. The LIN28B protein has an
extended C-terminus tail of approximately 41 amino acids longer than LIN28A, which
contains a nuclear localization signal131 (Figure 3A). However, both LIN28A and
LIN28B can localize in the cytoplasm and the nucleus130, 132.
Photoactivatable-ribonucleoside-enhanced crosslinking and immunoprecipitation
experiments showed that LIN28A and LIN28B proteins bind to thousands of mature
mRNAs at defined sites133. Given the overlap of LIN28A and LIN28B RNA binding
domains, they act redundantly. Among the strongest LIN28 binding mRNAs that showed
>10% average increase in transcript levels were the nuclear RNA binding proteins,
confirming a possible role in modulation of mRNA splicing134. In addition, histones, cell
cycle, insulin-PI3K-mTOR signaling pathway and the type-2 diabetes associated genes
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IGF2BP1 to IGF2BP3 and HMGA2 were among the direct LIN28 targets. However, the
most distinct mRNA that was regulated by LIN28B was LIN28B itself, which forms a
feed-forward pattern that maintain its own levels of expression and stem cells
properties133.

The LIN28/let-7 bi-stable switch
LIN28 was originally identified in C. elegans during mutagenesis screening for
genes that control developmental timing135. LIN28 gain of function mutations promoted
self-renewal and delayed hypodermal and vulval stem cell differentiation, whereas
LIN28 loss of function mutations accelerated vulval stem cell differentiation16.
LIN28 is highly expressed during embryogenesis and early larval development
but was post transcriptionally suppressed as cells differentiated and disappeared by
adulthood. The first two discovered miRNAs, lin-4 and let-7, were found to
posttranscriptional repress LIN28 by directly targeting complementary sequences in its
3’ UTR. Let-7 miRNAs are highly conserved and were originally discovered in a genetic
screening for C. elegans heterochronic mutants136. These miRNAs are important during
development, where repression by LIN28 is critical for maintaining pluripotency and
preventing differentiation. Loss of function of let-7 homologous mimicked LIN28 gain of
function phenotype highlighting their opposite roles in regulating differentiation.
In the mammalian genome, LIN28 is highly expressed in embryonic stem cells
(ESCs), in which pri-let-7 transcripts, but not mature let-7, were also highly
expressed137, 138. These findings led to the discovery that LIN28A and LIN28B directly
bind to pri-let-7 transcripts and inhibit its maturation through distinct mechanisms that
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are also conserved in C. elegans139-144. Mutagenesis studies have shown that both the
CSD and CCHC domains are required for LIN28A protein binding to the terminal loop
region of pre-let-7 in cell-free assays to block let-7 processing and inhibit its
maturation143, 145. Subsequently, a G-rich element (GGAG, GAAG, or AGGG) located at
the 3′ end of the loop region of pri-let-7 was shown to confer LIN28 protein binding and
resulted in inhibition of either DROSHA143 or DICER1 RNase III processing139, 146, 147 .
The same GGAGA motif was also present in 28% of mRNAs targets of LIN28A
identified by the LIN28A-HiTS-CLIP experiments134, 144. LIN28A also recruits terminal
uridylytransferase, Zcchc11, which leads to decay of the oligouridylated pre-let-7
miRNAs146, 147. In contrast, LIN28B mediated repression of let-7 is Zcchc11 independent
owing to the primary subcellular localization of LIN28B to the nucleoli and sequestering
it in the nucleoli thus preventing processing by the microprocessor complex148. This
data is strengthened by experiments which showed that depletion of Zcchc11 inhibited
tumorigenicity in LIN28A but not LIN28B expressing tumor xenografts and cancer cell
lines148. Therefore, LIN28 and let-7 form an evolutionarily conserved double negative
feedback loop, also known as bi-stable switch, that governs stem cell self-renewal 140,
142, 136

(Figure 3B)

LIN28 regulates cell development and metabolism
LIN28 also plays a role in the regulation of developmental timing, growth and
metabolism. A genome-wide association study (GWAS) of height from 15,821 subjects
identified LIN28B as one of 12 loci strongly associated with height, implicating the
lin28/let-7 pathway as a strong regulator of human height149. Two other GWAS studies
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reported that LIN28B was strongly associated with genetic regulation of female sexual
maturation and timing of human pubertal growth and development150, 151. Engineered
transgenic mice overexpressing LIN28A showed increased body size, crown-rump
length and delayed onset of puberty152. Further investigation revealed that these mice
showed increased glucose metabolism and insulin sensitivity consistent with
downregulation of let-7 targets Myc, Kras, Igf2bp1 and Hmga2152. Moreover,
overexpression of LIN28A or LIN28B in mice induced insulin sensitivity and resistance
to high-fat-diet induced diabetes153. This study found that LIN28 exerts this effect by
regulating components of the insulin-PI3K-mTOR pathway and overexpression of let-7
or muscle-specific loss of LIN28A reverses this phenotype. Furthermore, treatment with
rapamycin, an mTOR inhibitor, also inhibited the insulin sensitivity and enhanced
glucose metabolism induced by LIN28A overexpression153. Another GWAs study
showed that many LIN28 mRNA targets are involved in cellular metabolism further
confirming its role in regulating cellular growth and metabolism154. Therefore, LIN28
regulates cell metabolism through de-repression of let-7 mRNA targets and by directly
binding and regulating the expression of many genes that involved in cellular
metabolism independently of let-7.

LIN28 in stem cells and cell reprogramming
Stem cells are undifferentiated cells that have the capacity to become cells of
multiple lineages. They are generally classified as embryonic stem cells (ESCs),
induced pluripotent stem cells (iPSCs) or adult stem cells155, 156. ESCs are derived from
the ICM of the blastocyst during embryogenesis while iPSCs are generated by
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reprogramming somatic cells157, 158. ESCs and iPSCs are pluripotent and depending on
highly coordinated gene regulatory mechanisms, can differentiate into any cell type in
the body159. Adult stem cells such as neural stem cells and hematopoietic stem cells are
generally found among differentiated cells in specific tissues or organs. They can
differentiate into some or all of the specialized cells in the tissues or organ but cannot
become any cell in the body. All stem cells have self-renewal ability that allows them to
remain pluripotent as they undergo cell division.
LIN28A and LIN28B are important for the maintenance of the stem cell state
through let-7 dependent and let-7 independent mechanisms. Both LIN28A and LIN28B
are highly expressed in human ESCs and are highly involved in pluripotency. For
example, the promoter regions of LIN28A are occupied by the ESC transcription factors
Oct4, Sox2, Nanog and Tcf3, indicating that LIN28A expression is tied to expression of
other pluripotency factors in stem cells160. The increase in LIN28 expression represses
let-7 miRNAs, leading to increased expression of let-7 targets such as c-Myc, Sal4,
Hmga2, Igf2bps, LIN28 itself and various cell cycle regulators161. In addition, LIN28 has
been shown to associate with and regulate translation and stability of thousand mRNAs,
including Oct4, Cyclin B, Cdk4, Igf3, all of which promote ESC growth and repress
mRNAs important for oxidative phosphorylation, allowing for the low mitochondrial
metabolism typical of the primed pluripotency state132, 162-164 165.
Somatic cells can be reprogrammed into iPSCs by the introduction of the
reprogramming factors Oct3/4, Sox2, c-Myc and Klf4157. Another study showed LIN28A,
LIN28B are not only important for maintaining stem cell pluripotency but can also be
used in cell reprograming when combined with Oct4, Sox2, Nanog, eliminating the need
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for c-Myc which causes cell death and differentiation of ESCs166 165. Overexpression of
LIN28 was also shown to increase the rate of cell division and accelerated the kinetics
of iPSC reprogramming167.

LIN28 in the placenta
Despite the large amount of literature characterizing the function of LIN28 in stem
cell and embryonic development, little is known about the role of Lin28 in the human
placenta. In a recent work from our laboratory, we determined that LIN28B to be the
predominant paralog to be expressed in the human placenta. Primary cultures of CTs
and STs isolated from normal term placentas also showed higher expression of LIN28B
compared to LIN28A168. In situ protein localization of human placentas at term further
confirmed that LIN28B is primarily expressed in the STs and CTs, as opposed to the
decidual cells. We also show that LIN28B mRNA and protein levels were significantly
reduced in placentas of preeclampsia complicated pregnancies compared to placentas
of normal pregnancies. These data suggested that the decrease in LIN28B expression
may be an underlying contributing factor to the development of preeclampsia. In first
trimester human placenta, LIN28B was highly expressed in syncytial sprouts and its
expression increases from proximal, non-invasive, to distal invasive EVTs, while
decidual cells exhibited very little LIN28B expression. These findings further indicate its
role in early EVT invasion into the maternal decidua. Overexpression of LIN28B
significantly increased proliferation, migration and invasion of the EVT cell line
HTR8/SVneo, whereas knockdown of LIN28B in JEG3 cells (that highly express
LIN28B) decreased cellular proliferation168. Moreover, we showed that LIN28B regulates
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the expression of syncytin-1 which is involved in fusion of CTs to form the ST layer of
the placenta and also regulate the integrin subunit ITGβ4 which is enriched in
noninvasive trophoblasts, further confirming the role of LIN28B in regulating
trophoblasts differentiation to the EVTs and STs. We also showed that LIN28B
regulates the expression of the proinflammatory cytokine TNFα and the circulating
peptide hormone ELABELA, which are both associated with preeclampsia. Importantly,
we showed that LIN28B regulates expression of C19MC miRNAs.
Since preeclampsia is associated with shallow implantation, impaired trophoblast
invasion, and remodeling of the maternal spiral arteries resulting in insufficient placental
perfusion, we tested the effect of hypoxia on LIN28B expression and found that LIN28B
is drastically reduced upon exposure to hypoxia. The reduction in LIN28B was
associated with decreased SYN-1 expression and increased TNFα expression. These
data further confirm that LIN28B may play an important role in the pathology of
preeclampsia.
Other studies have previously reported that LIN28B is highly expressed in human
term placentas169. In human embryonic tissues, LIN28B expression increases during
early stages of gestation and plateaus between gestational weeks 7 and 9, indicating its
important role in the early stages of pregnancy170.
A previous study has investigated the role of LIN28A in human trophoblast
differentiation and invasion. They showed that LIN28A was detected in villous
trophoblasts, both CTs and STs of first trimester placental171. Knockdown of LIN28A in
the human trophoblast cell line ACH-3P that highly express LIN28A, increased let-7
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expression and decreased cell invasion suggesting that LIN28A is required for
trophoblast invasion171.
Another study showed that LIN28A was abundantly expressed in embryonic day
11.5 mouse placenta. LIN28A was detected in the chorioallantoic interface and labyrinth
layer, with little LIN28A staining in spongiotrophoblast or differentiated mouse
trophoblast giant cells (mTGCs). Decrease in LIN28A and increase in let-7 miRNA
levels were also reported after differentiation of mouse trophoblast stem cell into
mTGCs and in ACH-3P cells induced to syncytialize with forskolin treatment. Moreover,
knockdown of LIN28A in ACH-3P cells resulted in increased spontaneous
syncytialization accompanied by increase expression of ST markers hCG, LGALS13,
and ERVW-1 mRNA, and also increased the responsiveness to forskolin-induced
differentiation. However, unlike ACH-3p cells, knockdown of LIN28A in mouse
trophoblast stem cells did not induce syncytialization172.

LIN28 in Cancer
LIN28A and LIN28B are highly expressed in several primary human tumors
including colon, breast, lung, and cervical cancers. Recent studies have identified LIN28
as a highly specific marker of the aggressive embryonal CNS tumor with multilayered
rosettes (ETMR, previously known as ETANTR). In these tumors, the increase in LIN28
correlated closely with C19MC amplification124.
The increase in LIN28 was also observed in human cancer cell lines and was
associated with a decrease in let-7, and an increase in let-7 mRNA targets such as
Hmga2, Kras and c-Myc173 (Figure 4). Increased expression of c-myc due to reduction
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in let-7 is important, as c-myc transcriptionally activates LIN28 and other oncogenes to
establish a positive feed-forward loop173, 173. Studies have also shown evidence that
LIN28A supports cancer progression by promoting cell cycle progression and
proliferation through regulation of CDK2, CCND1 and CDC25A in cancer cell lines174, by
let-7 dependent and let-7 independent mechanisms174. Overexpression of LIN28 in
NIH/3T3 cells caused a depletion in let-7 expression and parallel increase in the
abundance of c-Myc, a let-7 target. LIN28 transformed cells formed colonies in soft agar
and tumors in nude mice indicating its role in enhancing metastases173.
Gain-of-function and loss-of-function studies showed that LIN28/let-7 signaling is
important for the maintenance of self-renewal with LIN28 and let-7 positively and
negatively regulating cancer stem cells respectively175. These studies provide evidence
to support the role of LIN28 in cancer progression and metastasis through let-7
dependent and let-7 independent mechanisms and underscore the significance of
increased LIN28 expression in aggressive tumors176.

31

Figure 3. Simplified schematic representation of LIN28A and LIN28B in normal
development.
(A) Conserved domains in the human LIN28 paralogs LIN28A and Lin28B. LIN28B (250
amino acids) is slightly longer than LIN28A (209 amino acids). CSD, cold shock domain;
CCHC, cysteine cysteine histidine cysteine domain; NLS, nuclear localization signal. (B)
LIN28 proteins are highly expressed in undifferentiated stem cells during normal
development. LIN28 blocks the maturation of let-7 miRNAs to facilitate stem cell
maintenance and proliferation. During differentiation, LIN28 expression decreases and
let-7 miRNAs are increased. Let-7 miRNAs decrease the self-renewal capacity of stem
cells which allows lineage commitment and terminal differentiation to occur.
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Figure 4. Schematic representation of Lin28 and let 7 in cancer.
In cancer, LIN28 and let 7 expression are often imbalanced. More aggressive cancers
show low let 7 expression and high Lin28 expression with increased self-renewal
capacity and tumorigenic potential.
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Chapter 4
Infantile Hemangioma
Prevalence and risk factors
Infantile hemangiomas (IH) are benign vascular tumors of childhood that affect
approximately 5% of all infants177-179. IHs are more prevalent among female infants with
some studies suggesting female-to-male ratios ranging from 1.4:1 to 5:1180, 181.
Currently, the definitive explanation for higher IH incidence in female infants is unclear.
Infants with IH are more likely to be white non-Hispanic, premature and be products of
multiple gestations. Multivariate logistic regression showed that low birth weight is the
most significant risk factor for IH. With every 500g decrease in birth weight, the risk of
developing IH increased by 40%182. Some studies report an increased incidence of IH in
infants after chorionic villous sampling92, 183 and amniocentesis184. Other pre-birth
factors associated with IH include older maternal age, pre-eclampsia and placenta
previa181. Studies have also shown a correlation between placental or perinatal hypoxia
and incidence of IH185. Other factors associated with IH include fertility drug use,
erythropoietin use, breech presentation, being the first born and familial clustering 180,
181, 186-189

.
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Phases of IH development
IHs have an atypical life cycle that involves at least two distinct evolutionary
phases: the proliferation phase and the involution phase. An intermediate phase
commonly referred to as a plateau phase occurs between the proliferation and
involution phases in which proliferating cells and cells undergoing apoptosis are likely at
an equilibrium190-193.
IH first present after birth as flat, raised patches with well-defined borders. The
proliferation phase is rapid and involves endothelial cell proliferation and formation of
disorganized blood vessels (non-leaky) composed of immature endothelial cells 194, 195.
The IH enlarges and develops a rubberier consistency during this period. Tumors are
often characterized by peripheral pallor and dilation of adjacent veins196. Painful
ulceration and scarring may develop during the proliferation phase due to the speed of
tumor growth. Clinical onset of IH is typically before the first 4 weeks of age and
duration of proliferation varies depending on morphology181, 191. A greater part of IH
growth occurs between 1 and 2 months of age with majority of IHs reaching 80% of their
eventual size by 3 months of age. Most growth of IH lesions is typically completed
around 5 months of age181.
In most IH cases, spontaneous tumor involution starts between 6 months and 1
year of age and continues for years with most regression occurring before 4 years of
age. A large retrospective study reported that involution terminated at a median of 36
months with 92% of tumors completing involution by year 4197. Importantly, completion
of the involution phase does not always mean complete resolution of the tumor and
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69% of IH cases leave behind noticeable changes in the skin, including fibrofatty
residuum, dyspigmentation, scars, telangiectasia and anetoderma.
Pathogenesis of IH
The pathogenesis of IH is complex and poorly understood. However, several
major hypotheses have been proposed. In 2000, North et. al. reported intense
endothelial immunoreactivity for the erythrocyte-type glucose transporter protein GLUT1 during all phases of IH development but not in any of 66 vascular malformations, 20
pyogenic granulomas or 7 granulation tissue specimens, establishing the viability of
GLUT-1 immunoreactivity as a diagnostic marker for IH198. In a retrospective study,
North et. al. showed that IH tissues also have high immunoreactivity for placental
molecular markers including Fc-γ receptor-IIb, merosin and Lewis Y antigen. These
markers were observed in placental villi and IH but not in micro vessels of normal skin
and subcutis199. These findings suggest a close association between the placenta and
IH and provide evidence to support a possible placental origin for IH. The placental
origin theory suggests that progenitor cells in IH embolize from the placenta during
pregnancy or birth due to placental disruption. This theory is also supported by clinical
studies that show that increased prevalence of IH correlates with placental disruption
arising from chorionic villus sampling, preeclampsia and placenta previa92, 183, 184. In
furtherance of this theory, a study by Barnes et al showed that the transcriptomes of the
human placenta and IH are highly similar, suggesting a placental origin for the tumor200.
The level of similarity was comparable to the similarities observed between a tissue and
its derived tumor. Therefore, a unifying theory of IH pathogenesis proposes that IH
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originates from abnormal proliferation and differentiation of a hemogenic endothelium
that exhibits a neural crest phenotype and can differentiate into mesenchymal,
endothelial, and neuronal cells. These cells are thought to originate from the placental
chorionic mesenchymal core which embolize to the developing fetus201.
Other studies have presented evidence to suggest that intrinsic endothelial
progenitor cells (EPC) contribute to the development of IH. This theory proposes that IH
originates from clonal expansion of circulating EPCs which results in the formation of
new blood vessels202. Supporting this theory, a study showed that blood samples of
infants with IH contained higher numbers of circulating EPCs203. Bischoff et al showed
that proliferating but not involuting or involuted IH tissues express an endothelial
progenitor cell marker, CD133-2, providing another evidence of EPCs in IH202.
Multipotential CD133-positive stem cells (HemSC) isolated from proliferative IH showed
high proliferative and clonogenic capacity and were able to differentiate into cells of
multiple lineages in vitro204. HemSCs and cord-blood EPCs are highly similar thus
suggesting that proliferating immature endothelial cells in IH could originate from
circulating EPC204. HemSC implanted into immunocompromised mice generated human
blood vessels after 7 weeks. Two months following implantation, the tumors showed
human adipocyte differentiation and a decrease in the number of blood vessels. These
results indicate that HemSCs are capable of recapitulating the unique IH life cycle204.
In addition, the IH cytokine niche provides a conducive environment for the denovo development of blood vessels due to the high expression of VEGFR-2 and
VEGFA194, 201. Furthermore, high expression of IGF2 promotes proliferation while the
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activation of the anti-apoptotic TRAIL-OPG pathway prevents apoptosis in IH201, 205. In
addition to increased expression of VEGF, other pro-angiogenic cytokines such as
bFGF, matrix metalloprotease (MMP) 9 and MMP-2 are increased while the expression
of the tissue inhibitor of metalloproteinases-2 (TIMP-2) was decreased in proliferative
IH195, 206, 207. These angiogenic factors are downregulated during involution while
inhibitors of angiogenesis such as interferon-β are upregulated during IH involution.
During IH involution, endothelial cells highly express caspases, which are known
markers of apoptosis208. Endothelial cell apoptosis during involution is also
accompanied by an increase in expression of markers of endothelial cell maturation
such as ICAM-1 and HLA-Dr209.
Low birth weight, a major risk factor for IH, is commonly caused by in utero
hypoxia. Thus, hypoxia has also been hypothesized to trigger a vascular response in
infants and numerous studies have highlighted its potential role in the development of
IH. Tissue ischemia increases and stabilizes the expression of hypoxia inducible factor1a and promotes the increase in expression of downstream effectors SDF-1a and
VEGF-A by hypoxic endothelial cells210. These effectors (SDF-1a, HIF-1a VEGF-A and
MMP9) have been shown to be upregulated in IH tissue and in blood from children with
proliferating IH211. These mediators facilitate the trafficking of progenitor cells to areas of
tissue hypoxia212. Hypoxia also induces the expression of GLUT-1, an important
hypoxia sensor, and IGF2 which are known to be highly expressed in IH213, 214.
Therefore, tissue hypoxia which leads to neovascularization due to the upregulation of
pro-angiogenic cytokines and trafficking of progenitor cells to hypoxic sites has been
hypothesized to contribute to the pathogenesis of IH. This hypothesis is further
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strengthened by reports of decreased blood flow in the skin preceding IH
development215 and a study that reported a synergistic effect between hypoxia and
estradiol on the upregulation of MMP-9, an important factor for EPC mobilization, in
endothelial cells in-vitro211.
Clinical classification of IH
IHs can be classified based on soft tissue depth during the proliferative phase as
superficial, deep or compound IHs. Superficial IHs appear as red, raised lesions with
well-defined margins on the surface of the skin and have little to no subcutaneous
involvement192, 196. These lesions have historically been described as strawberry
hemangiomas191. Deep IHs reside deep to the skin surface and have extensive
subcutaneous involvement. The surface of deep IHs may appear blue or unchanged.
Compound IHs combine both superficial and deep components in the same lesion196.
Superficial IHs can be further classified as telangiectatic, abortive, nonproliferative, nascent or arrested-growth IH. Although these lesions have little to no
proliferative phase and exhibit minimal growth, immnohistological study showed that
they display GLUT-1 immunoreactivity, confirming that they are true IHs216, 217.
Involution of abortive IHs is also more rapid, often occurring before 1 year of age
without leaving behind a fibrofatty residuum217.
IHs can also be classified as localized, segmental, indeterminate or multifocal
based on their clinical characteristics218. A large retrospective study by Haagstrom et al
defined localized hemangiomas as IHs that developed from a single focal point or
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localized to an area without an obvious developmental configuration. Segmented
hemangiomas were defined as IHs that possessed a configuration consistent with an
identifiable and/or substantial portion of a developmental unit219. Indeterminate
hemangiomas were defined as those which could not be easily classified as localized or
segmental while multifocal hemangiomas were defined as cutaneous lesions occurring
at more than 1 anatomical site220. The same study found that morphological subtype
was the single best predictor of complications and need for clinical intervention;
segmental hemangiomas were more likely to require treatment and lead to
complications compared to localized hemangiomas. Indeterminate hemangiomas had a
higher rate of complications and treatment than localized but lower than segmental
hemangiomas220. Complications tended to include ulceration, bleeding, airway
obstruction, visual and auditory compromise220.
Complications of IH
Due to the IH life cycle, most lesions do not require clinical intervention.
However, a significant minority of IH can develop complications that threaten vital
functions, quality of life and overall health of the patient and thus require treatment.
Complications attributable to IH include, ulceration, bleeding, airway obstruction,
feeding impairment, congestive heart failure and hypothyroidism221. Ulceration, the most
common IH complication, refers to a breakdown of the IH skin surface and occurs in
about 5% to 21% of IH cases222, 223. Ulcerations are more prevalent in lesions with a
superficial component and are more likely to occur during the proliferative phase224.
Ulcerations can lead to bleeding, secondary infection scarring and disfigurement and
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can cause significant pain. Bleeding is almost exclusive to ulcerated IH lesions and is
easily controlled with pressure when it occurs in non-ulcerated IH due to surface
trauma. Bleeding was reported in 41% of patients with ulcerated IH but was rarely
clinically significant225.
IH can lead to feeding impairment and cause a failure to thrive in patients with
IHs involving the perioral region or airway. These feeding difficulties are often caused in
by an oral sensory impairment and severe congenital laryngeal anomalies that can
make it harder for the patient to breath or swallow226. Furthermore, IH lesions that occur
in the periocular region can cause visual impairment such as astigmatism, strabismus,
anisometropia and lead to the development of amblyopia227, 228. High output congestive
heart failure has also been reported in a case of multiple cutaneous hemangiomas and
a case of cutaneous and diffuse liver hemangiomas229, 230. This congestive heart failure
is rare and is caused by arteriovenous shunting of a large volume of blood through the
tumor. Management of the heart failure usually improves the cardiac compromise and
the hemangioma221.
Medical interventions for IH
Complications arising from hemangiomas can be life threatening and necessitate
treatment. In the 1940s and 1950s aggressive irradiation and excision surgery were
widely used to treat hemangiomas with varying rates of success. A study in the late
1960s reported shrinkage of IH in a patient with multiple hemangiomas and
thrombocytopenia treated with systemic corticosteroid therapy231. In the following years
patients with proliferative IHs were treated with oral prednisolone and showed
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successful growth arrest with no rebound growth after treatment232. Although many
studies have shown that corticosteroid therapy is efficacious for the treatment of IHs233,
concerns about adverse effects of extensive systemic steroid administration persist
among physicians. Some adverse effects observed include cushingoid face, hirsutism,
personality change and gastric irritation. These effects usually resolved after steroid
therapy was completed234.
interferon-α, an important cytokine for the innate immune response to viruses,
has also shown efficacy for the treatment of corticosteroid therapy resistant IHs.
Interferon. This therapy was associated with transient side effects including fever,
neutropenia and skin necrosis235. However, significant side effects including
neurological toxicities and cortical and motor function impairment have been reported
thus precluding its use as a preferred therapy for IH221.
In 2008, Léauté-Labrèze et al reported a serendipitous finding that oral
propranolol, a non-selective b-adrenergic receptor blocker, effectively inhibited the
growth of IH236. Propranolol was used to treat children with IH who also presented with
increased cardiac output236. Propranolol treatment induced rapid changes in the
hemangiomas including a change in color from red to purple associated with a softening
of the lesion. The lesions achieved almost complete regression with residual skin
telangiectasias236. A follow-up study reported that propranolol administered with a
starting dose of 2 to 3 mg/kg per day in 2 or 3 divided doses was sufficient to produce a
rapid consistent and therapeutic response in patients with minimal side effects237. Due
to its efficacy and exceptional tolerance in infants, propranolol has since become the
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first-line therapeutic option for the management of IH. In 2014, the US Food and Drug
Administration approved a pediatric sugar, alcohol and paraben free formulation of oral
propranolol (Hemangeol: Pierre Fabre Dermatologie, Castres, France) for the systemic
treatment of proliferating hemangiomas.
In 2015, a large randomized controlled clinical trial of oral propranolol in infantile
hemangioma found that 88% of infants 1 to 5 months of age with proliferating
hemangiomas who received propranolol treatment showed marked improvement by
week 5 compared to 5% of patients who received placebo. Success was defined as
total or near total resolution of the hemangioma after 24 weeks of treatment and the
optimal dose was determined to be 3 mg/kg per day238. Additional studies have also
reported that oral propranolol is safe and effective for the treatment of complex and
cosmetically relevant hemangiomas239.
Although propranolol therapy for the management of hemangiomas in infants has
been reported to be very safe, 26 out of 1260 patients (2.1%) reported intolerable side
effects including severe sleep disturbance (17/26), severe agitation (3/26) and severe
respiratory disorders (4/26) and treatment had to be discontinued for these patients.
Other beta adrenergic receptor inhibitors that do not cross the blood-brain barrier such
as atenolol are well tolerated with fewer CNS side effects240 and do not compromise
efficacy241. Furthermore, a retrospective noninferiority study which compared atenolol
therapy to propranolol for the treatment of infantile hemangiomas found that atenolol is
as effective as propranolol and is less associated with risk of bronchospasm242. These
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studies indicate that atenolol can be used as an alternative therapy for patients who
experience CNS related side-effects when treated with propranolol.
β-Adrenergic receptor blockers
The β-Adrenergic signaling pathway mediates the fight or flight responses of the
sympathetic nervous system (SNS) through the catecholamine effectors epinephrine
and norepinephrine. Most major organs are innervated by SNS neural fibers which
release norepinephrine into target tissues in response to various physiological and
environmental stimuli. Effects of catecholamine release are mediated by α1-, α2-, and βadrenergic receptor families which are differentially expressed in different tissues and
perform their signaling function by coupling to G-proteins243.
β-adrenergic receptors are sensitive to epinephrine and norepinephrine and their
stimulation regulates broad cellular processes including growth control, muscle
contraction and metabolic regulation. Stimulation by norepinephrine or epinephrine
activates β-adrenergic receptor coupling to the Gs protein which stimulates the
synthesis of cAMP by adenylyl cyclase. This increase in cAMP mediates cellular
processes through 2 major effectors; protein kinase A (PKA) and exchange protein
activated by adenylyl cyclase (EPAC). PKA activation regulates cell differentiation,
motility, morphology and induces transcriptional alterations by phosphorylating
transcription factors, whereas EPAC signaling activates the MAPK pathway thus
exerting effects on cell proliferation and growth243, 244.
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Mechanism of action of β-Adrenergic receptor blockers in IH
Although the exact mechanism of action of propranolol in IH is still unknown,
some proposed mechanisms include vasoconstriction, modulation of the reninangiotensin system, inhibition of angiogenesis via downregulation of VEGF-A and
MMPs, inhibition of nitric oxide and stimulation of apoptosis196. Furthermore, all 3 β
adrenergic receptor subtypes have been shown to be expressed in IH lesions. β2
adrenergic receptor is localized mainly in endothelial cells and studies have also shown
β1 and β2 receptor expression in hemangioma endothelial cells, hemangioma pericytes
and HemSC 194, 245-247.
Activation of β2 receptors in endothelial cells by epinephrine induces vasodilation
through a signaling cascade that involves the activation of adenylyl cyclase, the release
of cAMP and the activation of PKA which leads to activation of endothelial NO synthase
and downstream NO release. NO released into the blood stream leads to the activation
of guanylate cyclase which induces the formation of cyclic guanosine monophosphate
(cGMP) and activation of protein kinase G. This cascade culminates in the relaxation of
vascular smooth muscle and vasodilation. β adrenergic receptor antagonists such as
propranolol can thus cause vasoconstriction by inhibiting vasodilation caused by β2
receptor activation248. Propranolol induced vasoconstriction decreases blood flow within
the hemangioma and accounts for the change in color from red to purple and the tumor
softening observed shortly after treatment is started236.
Propranolol has been shown to modulate growth-factor induced proliferation,
migration and tube formation by inhibiting VEGF induced tyrosine phosphorylation of
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VEGFR-2, MMP-2 secretion and inducing G0/G1 cell cycle arrest in endothelial cells in
vitro249. In addition, VEGF and bFGF are highly expressed in proliferative
hemangiomas211, 250, 251. Norepinephrine increases VEGF-A production in different
normal and diseased cell types 252-254. Therefore, by blocking β adrenergic receptors,
propranolol decreases VEGF-A mediated angiogenesis in IH. Indeed, propranolol
treatment of IH endothelial cells leads to decreased VEGF expression, decreased cell
proliferation and increased apoptosis by activating the caspase cascade and increasing
the expression of the pro-apoptotic p53 gene and Bax/Bcl-xl ratio255. Oral propranolol
was shown to decrease peripheral serum concentrations of VEGF and eNOS in patients
with IH 256. Another study found significant reductions in serum concentrations of VEGF,
bFGF and MMP9 after 8 weeks of propranolol treatment 257. These findings suggest that
propranolol exerts its therapeutic effects on IH lesions by modulating the expression of
these pro-angiogenic cytokines.
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Gap in knowledge and purpose of this dissertation
C19MC is the largest human cluster of miRNAs that is physiologically expressed
in pluripotent stem cells and the placenta. C19MC is imprinted and is regulated by DNA
methylation of an upstream CpG island. Chromosomal aberrations at 19q13.4 such as
amplifications which results in activation of C19MC have been found in benign tumors
and aggressive cancers. Many C19MC miRNAs share similar seed sequences and thus
target many of the same mRNAs. A number of studies have shown that individual
miRNAs of the C19MC play important roles in the regulation of stemness and cell
differentiation, proliferation, migration, invasion and resistance to viral infections.
However, investigating the physiological and pathological role of the entire C19MC
cistron in the placenta and in tumors has been challenging because of its size. Bacterial
Artificial Chromosome (BAC) technology has been employed to overexpress the entire
C19MC locus. Since BAC contains all the regulatory elements such as the upstream
CpG island that control its expression, it achieved modest upregulation. To address this
challenge and the gap in knowledge: 1) we employed the CRISPR/Sam technology that
avoided the imprinted upstream CpG island to transcriptionally activate the entire
endogenous C19MC cistron in different human cell lines in a highly efficient, specific
and reproducible manner; 2) we investigated the physiological role of the entire
C19MC cistron in trophoblast differentiation; 3) we determined the effect of C19MC on
cell reprogramming; and 4) we evaluated the effect of hypoxic conditions during
implantation and placentation on C19MC expression and EVT differentiation. Our
findings reveal the role of C19MC in cell reprogramming and maintaining epithelial
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aspects of trophoblast cells. Moreover, we show that hypoxic conditions promote EVT
differentiation at least in part by decreasing the expression of C19MC miRNAs.
C19MC is highly expressed in the human placenta and numerous benign tumors
and cancers. The increase in C19MC expression often correlated closely with
increased expression of the RNA-binding protein LIN28. However, the molecular
mechanisms that regulate C19MC and LIN28 have not been investigated. IH is a
benign tumor of infancy, characterized by rapid growth followed by spontaneous
involution. Although treatment is not required in a majority of cases due to natural tumor
involution, IH can cause significant morbidity which necessitates treatment. The current
first line IH treatment is the beta blocker propranolol, which induces rapid tumor
involution soon after treatment onset. In addition, C19MC miRNAs are highly expressed
in IH and decreases in circulating C19MC miRNA levels correlated with tumor phase
and with propranolol treatment. Although C19MC miRNAs and LIN28 protein expression
have been strongly correlated in some tumors, it has not been reported in IH. In
addition, the effect of propranolol on C19MC and the LIN28/let 7 bi-stable switch has
not yet been determined. To address this gap in knowledge, we analyzed the
expression of LIN28B in proliferative IH, involuted IH and propranolol treated IH
samples. Using sRNAseq, we also examined the expression of miRNAs differentially
expressed in IH and in propranolol treated iPSCs. We show that overexpression of
LIN28B in HEK293 cells induces the expression of miR-516b, a C19MC miRNA without
altering the methylation status of the C19MC upstream CpG island or increasing
transcription in the region, indicating that LIN28B increases the expression of miRNAs
of the c19MC in a methylation independent mechanism. Moreover, the expression of

48

both C19MC miRNAs and LIN28B was reduced by propranolol treatment. Based on our
findings, we propose that propranolol induces IH involution by altering the LIN28/let 7
balance and decreasing the expression of C19MC miRNAs.
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Chapter 5
Materials and Methods
Ethical approvals and Tissue specimens
Institutional review board approval for collection of resected human hemangiomas was
obtained from Columbia University College of Physicians and Surgeons (IRB
#AAAA9976). The clinical characteristics of the patients used for this study are shown in
Table I. Term placental tissues from normotensive patients who were delivered by
cesarean section were obtained from Tampa General Hospital/ University of South
Florida (IRB # 00015578). Written informed consent was obtained from all patients. Deidentified foreskin was used as normal infant skin (NS) and obtained from Tampa
General Hospital, Tampa Florida. Placental sections from the first trimester (7 and 8week gestation, n = 2) and early human pregnancies (20-week gestation, n=2) were
obtained from a previously banked paraffin tissue bank, under approval by Yale
University Human Investigation Committee and by the institutional review board of the
University of South Florida. Animal study procedures were approved by the Institutional
Animal Care and Use Committee (IACUC, R IS00004309) at the Morsani College of
Medicine, University of South Florida.
Cell Culture
The human iPSC line SCVI274 was a gift from Dr Joseph C. Wu at Stanford
Cardiovascular Institute, Stanford University School of Medicine. iPSCs were cultured
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on matrigel coated 6-well plates and maintained in Essential 8 medium (A1517001, Life
Technologies) and passaged every fourth day. HEK293 cells (Stratagene #240085) and
HeLa cells (ATCC® CCL-2™) were maintained in DMEM supplemented with 10% heatinactivated fetal bovine serum (Sigma-Aldrich). MCF7 cells (ATCC® HTB-22™) were
maintained in EMEM supplemented with 10% FBS and PC3 (ATCC® CRL-1435™) were
maintained in F-12K medium supplemented with 10% FBS. Normal Human Dermal
Fibroblasts (NHDF, Lonza CC-2511) were purchased and maintained in FGM-2
BulletKit (Lonza CC-3132). The HemSC line H42 was a gift from Dr. June Wu at the
Department of Surgery, Columbia University College of Physicians and Surgeons.
Briefly, freshly dissected IH tissues were digested in 0.2% collagenase A (Roche
Diagnostics, Indianapolis, IN). Suspension of single cells were selected using antiCD133–coated magnetic beads (Miltenyi Biotec) and cultured on fibronectin-coated (1
μg/cm2) plates with endothelial growth media-2 SingleQuot (EBM-2, CC-3156;
Cambrex) supplemented with 20% FBS 258, 259. HemSCs were maintained in EBM-2
SingleQuot media supplemented with 20% FBS. Propranolol (Sigma-Aldrich, P0884)
was reconstituted in DMSO and used at 50 μM concentration for all experiments.
Transient transfection
For LIN28B over-expression experiments, 105 HEK293 cells per ml were seeded in 12well plates (Greiner Bio). The following day, the cells were transfected with pcDNA3FLAG-Lin28B, a gift from Narry Kim (Addgene plasmid # 51373) using Lipofectamine
2000 (Life Technologies) according to the manufacturer’s instructions. The culture
medium was changed 24 hours after transfection and total RNA was harvested at
72 hours.
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Cell proliferation
iPSCs were grown in 6 well plates and split 1:10 at 3-day intervals. Cells were seeded at
subconfluency on a matrigel-coated 96-well plate in Essential 8 media then treated with
50 μM propranolol or vehicle control for 72 hours. WST1 proliferation assays were
performed as previously described260.

Cell viability
The viability of iPSCs after propranolol treatment was analyzed by staining of live and
dead cells with calcein AM and Propidium iodide (PI), respectively, 72 hours after
treatment. Cells were washed with PBS before the addition of 2 µM calcein AM and 4 µM
PI solution. Fluorescence microscopy images were captured after 15 minutes.

Design and cloning of C19MC-specific sgRNAs
Single guide RNAs that target upstream region of C19MC were designed using the
ATUM CRISPR sgRNA design tool. Two guide sequence oligos, 759-sgRNA 5'CACCGCAAATCCTAGGCCTGCCCTG and 620-sgRNA5'CACCGGTGAGCTGATGATCGCTCCA, were cloned into the lenti sgRNA(MS2)_zeo
backbone (a gift from Dr. Feng Zhang261, Addgene #61427) using a Golden-Gate
sgRNA cloning protocol and transformed into Stbl3 recombination deficient competent
cells (Life Technologies, C7373-03). Ampicillin resistant clones were selected and
verified by sequencing.

52

Transient activation of C19MC cistron
HEK293 (105 cells/well) were seeded in 12-well plates (Greiner Bio). The following day,
the cells were transfected with a 1:1:1 mass ratio of sgRNA, MS2-P65-HSF1_Hygro and
dCAS9-VP64_GFP (gift from Dr. Feng Zhang261 Addgene #61426 and #61422,
respectively) using Lipofectamine 2000 (Life Technologies) according to the
manufacturer’s instructions. Culture medium was changed after 24 h. Total RNA was
harvested after 72 h.

iPSC generation
Three micrograms of 759-sgRNA, MS2-P65-HSF1_Hygro and dCAS9-VP64_GFP in a
1:1:1 mass ratio alone or together with three micrograms of pCXLE-hOCT3/4-shp53-F,
pCXLE-hSK and pCXLE-hUL (gift from Dr. Shinya Yamanaka262 Addgene #27077,
#27078 and #27080, respectively) at 1:1:1 mass ratio were electroporated into 6 × 105
NHDF cells using nucleofector (Lonza) and Amaxa Human Dermal Fibroblast
Nucleofector Kit (Lonza, CC-2511) according to the manufacturer's instructions. Cells
were seeded on 0.1% gelatin coated 6 well plates. After 3 days incubation, cells were
trypsinized and re-plated at 2 × 105 cells onto 100-mm matrigel-coated dishes. The next
day culture medium was replaced with mTeSR1 medium (STEMCELL Technologies,
85857). Colonies were counted from 20 to 30 days after plating and colonies similar to
ESCs in morphology were harvested for further expansion and maintained in E8 media
(Life technologies, A1517001) for at least 10 passages.
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In Vitro differentiation of iPSCs
Human iPSCs were harvested by treating with collagenase IV for 30 minutes at 37oC.
Cell clumps were transferred to ultra-low attachment plates (Fisher Scientific, 07-200601) and maintained in DMEM supplemented with 20% FBS. Media was changed every
other day. After 7 days in suspension culture, embryoid bodies were transferred to
gelatin coated 8-well glass chamber slides and cultured for a further 10 days.
Expression of the different germ layer markers were quantified by qRT-PCR.
Differentiation of iPSCs into CTs, STs and EVTs was performed as previously described
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. Briefly, iPSCs (cell line SCVI274) were treated for 2 days with EMIM medium

containing KnockOut DMEM /F12 medium (Thermo Fisher Scientific, 12660012)
containing 1% insulin-transferrin-selenium A (Thermo Fisher Scientific 41400045), 1x
nonessential amino acid (Sigma-Aldrich M7145-100ML), 2% (wt/vol) BSA (Thermo
Fisher Scientific, AM2618) 2 mM L-glutamine (Life Technologies, 25030-081) 100
ng/mL heparan sulfate proteoglycan (Sigma- Aldrich, H4777-.1MG). and then switched
to EMIM medium supplemented with 10 ng/mL human BMP4 ((R&D Systems, 314-BP010) for additional 5 days, at which point they were designated hPSC-derived CTs. For
STs and EVTs differentiation, the hPSC-derived CTs were passaged using 0.25%
trypsin and replated on Matrigel (Corning, 354277) coated plates (1:200) in FCM
[KnockOut DMEM/F12 containing 20% (vol/vol) KnockOut serum replacement
(Knockout SR; Thermo Fisher Scientific, 10828010), 1x GlutaMAX (Thermo Fisher
Scientific, 35050061), and 1x nonessential amino acid, 0.1 mM 2-mercaptoethanol
(Thermo Fisher Scientific ,21985023); conditioned on irradiated mouse embryonic
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fibroblasts for 24 h], supplemented with 10 ng/mL human BMP4 and incubated in
normoxic (21% Oxygen) and hypoxic (1% oxygen) conditions respectively for the
indicated number of days.

Teratoma formation and immunohistochemistry
iPSCs were mixed with Matrigel and injected into each flank of NOD-SCID mice.
Tumors were harvested at 4 weeks post-injection, fixed in 4% paraformaldehyde and
embedded in paraffin. Sectioned tumors were immunostained with a human antimitochondria specific antibody (Abcam cat# ab92824) at 1:1000 dilution following the
manufacturer’s protocol and nuclei were counterstained with hematoxylin.

Alkaline Phosphatase staining
Alkaline phosphatase histochemical staining was performed using Alkaline phosphatase
detection kit (Millipore cat# SCR004) as described in the manufacturer’s instructions.
Briefly, cells were fixed with 4% paraformaldehyde for 10 minutes and washed once
with rinse buffer (20 mM Tris-HCl, pH 7.4 and 0.05% Tween 20). Staining solution was
added to the wells, and the plates were incubated in the dark for 25 min. Bright field
images were then obtained using a microscope.
RNA isolation, RT–PCR and quantitative PCR (qPCR)
Total RNA was isolated from human tissues and cultured cells using an RNeasy Mini Kit
(Qiagen) and stored at -80°C in RNAse-free water. For RT–PCR analysis, 1 µg total
RNA was reverse transcribed using random hexamer or oligodT primers and M-MuLV
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reverse transcriptase (New England Biolabs) according to the manufacturer's
specifications.
For transcription assessments, cDNA products were amplified for 25 PCR cycles using
previously described P0, P1, P5, P8 and P9 primer sets97 and Q5 High Fidelity DNA
polymerase (New England Biolabs). PCR products were run on 1% agarose gels and
imaged with a BioDoc-It imaging system (UVP). All primers used in this study were
obtained from Sigma Aldrich. To assess relative mRNA and miRNA expression levels,
quantitative PCR (qRT-PCR) of cDNA products was performed using the following
ThermoFisher TaqMan qRT-PCR probes: LIN28A (Hs00702808_s1), LIN28B
(Hs01013729_m1), SOX2 (Hs01053049_s1), NANOG (Hs04399610_g1), OCT4
(Hs00999632_g1), CDH2 (Hs00983056_m1), SERPINE1 (Hs00167155_m1), TWIST1
(Hs01675818_s1), SNAI2 (Hs00161904_m1), ACTA2 (Hs00426835_g1), TUBB3
(Hs00801390_s1), GATA4 (Hs00171403_m1), CDX2 (Hs01078080_m1), PSG4
(Hs01923769_s1), p63 (Hs00978340_m1), HLAG (Hs00365950_g1), GAPDH
(Hs02786624_g1) miR-515-5p (001112), miR-516a-5p (002416), miR-516b (001150),
miR-517a (002402), miR-518c (002401), miR-519d (002403), let-7a (000377), let-7c
(000379), U18 (001204). Taqman probes were used according to manufacturer’s
instructions with TaqMan Fast Advanced Master Mix and QuantStudio 3 instrument (Life
Technologies) as previously described264. Data were analyzed by the ΔΔCt method:
target Ct values and were normalized to GAPDH Ct values.
DNA isolation and HpaII sensitivity assay
DNA was isolated from cultured cells using the Blood and Tissue Kit (Qiagen) and
stored at -20oC in RNAse-free water. 300ng of DNA was digested with 2 µl of 10,000
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units/ml HpaII (NEB) restriction enzyme or water (mock) for 12 hours. qPCR was
performed using 60 ng of DNA from mock or HpaII reactions with primers designed to
amplify 340bp region containing 6 HpaII restriction sites in the C19MC CpG island (F:
5’-GCGCCGGCTGCACGTCCCTTAGGAG and R:5’CCCGCTGCCTGGAAGTATCGCCACC) and SYBR Green (SYBR Green PCR Master
mix, Bio-Rad) in a QuantStudio 3 instrument (Applied Biosystems). HpaII sensitivity was
calculated using the formula [1 − 2Ct(mock) − Ct(HpaII)] × 100% as described265.

Luciferase reporter plasmid, transfection and luciferase assay
The CDH2 3’ UTR was amplified by PCR using the following primer pairs that contain
the NOT1 restriction site (F: 5’ - ATGCGCGGCCGC
TGTAGCAGTTAAAAAGAGGTAGGTG and R:5’- ATGCGCGGCCGC
AACTTTGTAGTCTACTAGCACAGTG. PCR product and PGL2 basic (Promega,
#E1641) were digested with the NOT1 restriction enzyme and ligated. The insertion
orientation of the CDH2 3’UTR was confirmed by DNA sequencing. 104 HEK293were
plated and transfected after 24 hr with 1:1:1 mass ratio of 759 sgRNA, MS2-P65-HSF1Hygro and dCAS9-VP64-GFP using Lipofectamine 2000 (Life Technologies) according
to the manufacturer’s instructions. Culture medium was changed after 24 hours. At 48
hours from the transfection, CDH2 3’ UTR and PGL4.74 (Promega cat #E6921) were
co-transfected in a 4:1 mass ratio. Firefly and Renilla luciferase activity were measured
after 24 hours using the Dual Glo Luciferase Reporter Assay System (Promega
#E1910) and a luminometer (Cytation 3 cell imaging multi-mode Reader, BioTek
Instruments).
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Immunofluorescence
Paraffin embedded infantile hemangioma and placenta sections (10 μm) were
immunostained with primary antibodies against LIN28B 40 ug/ml (Abcam Cat#
ab71415, RRID:AB_2135050) and GLUT1 3.4 ug/ml (Abcam Cat# ab40084,
RRID:AB_2190927) overnight at 4°C. Sections were washed 3 times in PBS and
incubated with 4 ug/ml secondary antibody Alexa Fluor 488 (Life Technologies Cat#
a21202, RRID:AB_141607) for GLUT1 and alexa fluor cy3 (Life Technologies Cat#
a10520, RRID:AB_2534029) for LIN28B for 30 minutes at room temperature. The
sections were then washed with PBS and mounted with ProLong Diamond Antifade
Mountant with DAPI, (Invitogen). Confocal images were obtained using an Olympus FV
1200 instrument. Immunofluorescence intensities were measured using ImageJ
software as described266. Fluorescence intensities were normalized to background
intensities of secondary antibody only controls.

Immunoblotting
Immunoblot analyses were performed as previously described267 using 24 ng/ml
antibodies against GAPDH (Cell Signaling Technology Cat# 2118L RRID:AB_561053),
0.2 µg/µl antibodies against LIN28B (Abcam Cat# ab71415 RRID:
AB_2135050) followed by IRDye 680 donkey anti-rabbit IGG secondary antibodies(0.2
μg/ml, LI-COR, 926-68073 RRID:AB_10954442). Immunoblots were imaged
using the Odyssey Infrared Imaging System (LI-COR) and quantified using Image
Studio software (LI-COR).
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In situ hybridization
In situ hybridization for hsa-miR-517a/c, a miRNA of the C19MC, in early pregnancy
placental sections was performed according to the manufacturer’s instructions. Briefly,
paraffin embedded sections were deparaffinized in xylene then rehydrated by a series of
graded alcohol washes. In situ hybridization was then performed using 40 nm 5’,3’
digoxigenin-labeled locked nucleic acid probe for hsa-miR-517a/c or scrambled negative
control using the Exiqon in situ hybridization optimization kit according to the
manufacturer protocol (ISH kit that include the scramble probe: Exiqon, 90005, miR517a/c probe: Exiqon, 611715-360). Hybridization and post-hybridization graded SSC
washes were performed at 55oC. The sections were then blocked, and the probes were
detected using alkaline phosphatase conjugated sheep anti-digoxigenin Fab fragments
(Roche, 11093274910). The signal was developed using NBT/BCIP (Roche,
11697471001) as a substrate that produces dark-blue indigo precipitating dye followed
by nuclear counterstaining with Nuclear Fast Red (Vector laboratories, H-3403). The
sections were then dried and covered for later image analysis

Immunohistochemistry
Cytokeratin and vimentin immunostaining on early pregnancy placental sections was
performed as previously described 268. Briefly, paraffin embedded sections were
deparaffinized in xylene and rehydrated in a series of graded alcohol washes followed
by antigen retrieval by boiling in citric acid. Endogenous peroxidase activity was
quenched by incubation in 3% H2O2. The sections were then blocked using normal
horse serum followed by incubation with the primary antibody (mouse-anti-cytokeratin,
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Dako M7018, 1:600, RRID: AB_2134589). The following day cytokeratin was detected
by incubation with the secondary antibody (biotinylated horse-anti-mouse, Vector
Laboratories BA-2000, 3.75ug/ml, RRID: AB_2313581) along with the avidin-biotinperoxidase complex (Vectastain ABC Kit, pk6200, Vector Laboratories). The signal was
then developed using 3,3- diaminobezidine (sk-4100, Vector Laboratories) as substrate.
The sections were then thoroughly washed then blocked using normal donkey serum
followed by overnight incubation with the primary antibody (chicken-anti-vimentin,
Abcam ab39376, 1ug/ml, RRID: AB_778827). The following day vimentin was detected
by incubation with the secondary antibody (donkey-anti-chicken, Jackson
ImmunoResearch 703-065-155, 1.2ug/ml, RRID: AB_2313596) along with avidin-biotinalkaline phosphatase (Vectastain ABC-AP, Vector laboratories AK-5200). The signal
was then developed using Vector Red AP substrate (Vector Red, Vector Laboratories
SK-5100) followed by nuclear counterstaining with hematoxylin. The sections were then
dried and covered for later image analysis.
miRNA- and mRNA-sequencing
Two μg of total RNA were converted into a small-RNA cDNA library according to the
previously published protocol269. Briefly, the RNA input for each sample was ligated to a
3’ adaptor barcoded sequence, pooled, size selected and gel purified, followed by 5’
adapter ligation and then subjected to size selection and gel purification. The cDNA
library preparation was completed by second strand synthesis using SuperScript III,
alkaline RNA hydrolysis, and PCR amplification for 10 cycles. mRNA libraries were
prepared by utilizing the Illumina TruSeq Stranded mRNA LT protocol using 500 ng total
RNA and NEB’s Protoscript II reverse transcriptase for the first-strand cDNA synthesis
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according to the manufacturer’s protocol. Individual RNAseq libraries were quality
controlled on an Agilent TapeStation with a High Sensitivity D1000 ScreenTape.
Indexed samples were quantified using the Qubit dsDNA HS assay and pooled at
equimolar concentration (10 nM). The libraries were sequenced on an Illumina NextSeq
500 sequencer 75-bp paired-end in mid-output mode in the Genomics Core Facility of
The Rockefeller University.
Bioinformatics analysis
The miRNA read annotation for sRNAseq experiments was performed as previously
described270, 271 using an slightly updated, manually curated miRNA reference based on
previous work 272. For nomenclature of single miRNAs and definition and nomenclature
of miRNA cistrons (or “pre-cursor clusters”) see Figure S1 of Akat et al. 273. The
RNAseq data was aligned to the Human Genome Build 38 using the STAR aligner274
(version 2.0.4j) allowing for two mismatches. Expression values (count matrices) were
generated using featureCounts against gene definitions from Ensembl release 88 (GTF
file) using fractional counting of multi-mapping reads.
Statistical analysis
sRNAseq and RNAseq data analyses were performed using the R statistical language.
Differential analysis was performed using the Bioconductor package edgeR. All RTPCR and immunoblotting data are reported as mean ± standard error of the mean
(SEM). All data were tested for normality. Comparisons between two groups of normally
distributed data were made by two-tailed Student’s t-tests with correction for unequal
variance, while comparisons of data that was not normally distributed were done using
Mann-Whitney U tests. Comparisons with more than two groups were subject to one61

way ANOVA with Dunnett’s post hoc tests against controls. Statistical testing was
performed with IBM SPSS 24. P < 0.05 was considered statistically significant or as
specified in the relevant tables and figure legends.
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Table 1. Clinical characteristics of patient samples obtained from Columbia
University College of Physicians and Surgeons (IRB #AAAA9976)

Identifier

Patient
age

Sex

25

1.5 months

Female

84

4 months

24

IH location

Treatment

Stage of IH

Preparation

Subglottic

None

Proliferating;
obstructive

Male

Left cheek

Propranolol

propranolol

5 months

Female

Retroauricular

None

Proliferating; ulcerated

24

5 months

Female

Retroauricular

None

Ulcerating

66

5 months

Male

Upper back

Propranolol

Proliferating; ulcerated

82

6 months

Female

trunk (left side)

None

Proliferating

62

7 months

Female

Scalp

Propranolol

Proliferating; ulcerated

63

9 months

Female

Scalp

None

Proliferating; bleeding

26
21b
19

15 months
18 months
18 months

Female
Female
Female

Forehead
Forehead
Chin

None
None
None

Involuting
Stable/involuting
Stable

27

24 months

Female

Anterior neck

None

Involuting

27
54

24 months
24 months

Female
Female

Anterior neck
Right shoulder

None
None

Involuting
Stable/involuting

36

24 months

Female

Cheek

None

Involuting

55

30 months

Female

Chest wall

None

Involuting

65

36 months

Female

Cheek

Propranolol

Pockets of proliferation

28

36 months

Female

Chin

None

Ulcerating/proliferating

80

36 months

Male

RUE

None

Involuted

23

36 months

Female

cheek

None

Involuted

18b

84 months

Female

Trunk (left
side)

None

Involuting

Paraffin
embedded
Paraffin
embedded
Paraffin
embedded
Fresh
Paraffin
embedded
Paraffin
embedded
Paraffin
embedded
Paraffin
embedded
Fresh
Fresh
Fresh
Paraffin
embedded
Fresh
Fresh
Paraffin
embedded
Fresh
Paraffin
embedded
Fresh
Paraffin
embedded
Paraffin
embedded
Paraffin
embedded
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Chapter 6
Chromosome 19 MicroRNA Cluster Enhances Cell Reprogramming by Inhibiting
Epithelial to Mesenchymal Transition
Introduction
Human embryonic implantation into the uterus requires extensive, coordinated
attachment and invasion of the maternal endometrium by fetal trophoblasts. After
fertilization and while still in the fallopian tube, the morula differentiates into the
blastocyst, which consist of the inner cellular mass and an outer layer of epithelial cells,
called trophectoderm, that eventually develops into the placenta275. Shortly before
attachment, the highly mitotic cytotrophoblast (CTs), derived from trophectoderm,
differentiate into multinucleated syncytiotrophoblast (STs) or extravillous trophoblast
(EVTs). The STs form the outer layer of the villous and regulate the maternal-fetal gas
exchange, waste elimination and nutrient uptake. The EVTs, consist of two major
subtypes; interstitial EVTs and endovascular EVTs. Interstitial EVTs invade the decidua
and inner myometrium to anchor the chorionic villi to the decidua and uterine wall while
endovascular EVTs penetrate and remodel the maternal spiral arteries to transform
them into high-flow, low-resistance vessels which facilitate placental perfusion and
nutrient uptake by the fetus20, 276.
EVT invasion is a highly regulated process and inadequate invasion can lead to
placental hypoperfusion resulting in several early pregnancy complications including
early pregnancy loss, fetal growth restriction, and preeclampsia277, 278. EVT
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differentiation involves extensive changes in which cells lose their cell junctions and
apical-basal polarity and acquire migratory and invasive capacity, a process that
requires the epithelial to mesenchymal transition (EMT). EMT is facilitated by
transcription factors such as SNAIL, SLUG, TWIST and zinc-finger E-box-binding
protein (ZEB) which downregulate epithelial markers and induce the expression of
mesenchymal cell markers such as N-cadherin (also known as CDH2) and vimentin279.
Studies have shown that first trimester CTs and EVTs display gene expression
characteristics of epithelial and mesenchymal cells, respectively, indicating that EMT is
involved in CT to EVT differentiation 280, 281.
MicroRNAs (miRNA) are heavily involved in the regulation of EMT282. Human and
primate CTs highly express a unique cluster of miRNAs found on chromosome 19
(C19MC) 97. This miRNA cluster spans approximately 100 kb and contains 46 miRNA
genes that produce 56 mature miRNA species97, 283. It is epigenetically controlled by
imprinting, with only the paternal allele expressed in the placenta97. C19MC miRNAs are
highly expressed in villous CTs and STs but their expression is significantly reduced in
EVTs 110, 284. Furthermore, bacterial artificial chromosome (BAC)-mediated
overexpression of C19MC attenuated cell migration and invasion phenotype by
regulating enzymes and proteins that regulate cell motility indicating its role in the
regulation of EVT invasion105.
C19MC miRNAs are also highly expressed in embryonic stem cells (ESCs)
together with other miRNA clusters including miR-302/367, miR-17/92, miR-200 and
miR-371-37398. Moreover, sixteen of the C19MC miRNAs share the same seed
sequence with the miR-302/-372 family 102. Reprogramming of somatic cells into
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induced pluripotent stem cells (iPSCs) relies upon ectopic expression of the OSKM
transcription factors (OCT4, SOX2, KLF4 and MYC) or the OSLN factors (OCT4, SOX2,
LIN28 and NANOG)157, 166, 285. iPSC generation from human fibroblasts by OSKM,
requires a mesenchymal-to-epithelial transition (MET) orchestrated by the suppression
of pro-EMT signals and activation of a cellular epithelial program37. Importantly,
overexpression of miR302/367 cluster has been shown to induce reprogramming
human somatic cells without the requirement for OSKM transcription factors103.
Furthermore, the miR302/367 cluster, miR-291-3p, miR-294 and miR-295 enhanced
reprogramming efficiency when co-expressed with OSKM transcription factors 91, 286.
Additionally, miR-524-5p, a member of the C19MC has been shown to promote
reprogramming to pluripotency in the presence of OSKM by targeting EMT related
genes, promoting cell proliferation and inhibiting apoptosis287.
To date, the role of the entire C19MC cluster in regulating EMT, trophoblast
differentiation during placentation and somatic cell reprogramming is not yet fully
understood. We hypothesize that C19MC is crucial for maintaining epithelial aspects of
trophoblast cells and that downregulation of C19MC expression during early
placentation by hypoxic conditions induces EMT and differentiation of CTs toward
EVTs.
Results
C19MC is expressed in non-invasive CTs and STs of the placenta
To determine the cellular localization of C19MC miRNAs in the placenta from
early pregnancies, we performed in situ hybridizations (ISH) with probes for miR-517a/c
on first trimester and early pregnancy placental sections. Control scrambled probe was
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used for negative control. To distinguish trophoblasts from decidual tissue, adjacent
consecutively cut sections were subjected to immunohistochemical staining for
cytokeratin and vimentin, respectively. Stronger miR-517a/c expression was found in
CTs, STs, and proliferative non-invasive trophoblastic cell columns (proximal
cytotrophoblastic cells), in anchoring villi and C19MC expression gradually decreased in
the invasive EVTs distal cytotrophoblastic cells) invading the maternal decidua.
Moreover, in maternal decidual cells, miR-517a/c was detected (Figure 5A). ISH for
miR-517a/c on term placental sections also showed strong expression of C19MC in
villous trophoblasts (VTs) (Figure 5B). These data suggest that invasive CT
differentiation is associated with inhibition of C19MC expression.

Transcriptional activation of C19MC
To investigate the role of C19MC in trophoblast cell differentiation, we employed
the dCas9-based transcription activation system that combines a single-guide RNA
(sgRNA) that contain two MS2 RNA aptamers, a catalytically inactive Cas9 variant
fused to VP64 gene activation system and MS2-p65-HSF1 activation helper protein,
designated as synergistic activation mediator (SAM) system261. To avoid the imprinted
CpG island of the C19MC cistron located 17 kb upstream of the first miRNA of C19MC,
two different sgRNAs were designed. The 620-sgRNA binds at ~579 bp upstream of the
first miRNA of the C19MC, whereas 759-sgRNA binds at ~171 bp upstream of the first
two miRNAs of the C19MC (Figure 6 A and B).
To determine the specificity and the extent of overexpression of the entire
C19MC miRNA cistron using this method, sRNAseq analysis of HEK293 cells
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transiently transfected with 759-sgRNA/SAM or 620-sgRNA/SAM for 72 hours was
performed. To assess reproducibility, we performed an additional experiment using 759sgRNA/SAM. Strikingly, sRNAseq analysis showed consistent 2- to 7984-fold
upregulation of 45 miRNAs in all three independent experiments (threshold: ≥ 2- fold,
FDR ≤ 0.20), 43 of which belong to the C19MC miRNA cluster (Figure 7A,
Supplementary Table SI). Importantly, miRNAs of the miR-371-373 cluster that is
located in close proximity to C19MC were not induced by either 759-sgRNA/SAM or
620-sgRNA/SAM. Interestingly, other ESC-enriched miRNAs such as miR-302a-5p,
miR-20b, miR-200a, miR-200b, miR-200c and miR-141 were also upregulated (FDR ≤
0.20) in HEK cells transfected with either 759-sgRNA/SAM or 620-sgRNA/SAM
(Supplementary Table SI). On the other hand, no overlap was found in the
downregulated miRNAs (Figure 7B, Supplementary Table SI)
The expression of 4 randomly selected C19MC miRNAs was validated by qRTPCR, which showed significant upregulation of all 4 C19MC miRNAs (300- to 31,000fold, p ≤ 0.05), while the expression of miR-21, a non-C19MC miRNA, was unchanged
confirming the specificity of the SAM system (Figure 7C). To test reproducibility of this
method, 759-sgRNA/SAM was transfected into an immortalized invasive trophoblast cell
line, the HTR8/SVneo cells, which does not highly express C19MC and found that all 4
selected miRNAs were increased by 16- to 244-fold compared to GFP transfected
control (Figure 7D). Furthermore, transfection of 759-sgRNA/SAM or 620-sgRNA/SAM
in different human tumor cell line including MCF7 and PC3 cells successfully activated
the transcription of C19MC (data not shown). These data demonstrate that the
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CRISPR/SAM system can be used to selectively and consistently activate the entire
C19MC cistron that spans over 100 kb.

C19MC downregulates predicted mRNA targets
To test whether C19MC miRNAs regulate genes involved in trophoblast differentiation,
we performed RNAseq analysis of HEK293 cells transiently transfected for 72 hours
with either 620-sgRNA/SAM or 759-sgRNA/SAM (Supplement Table SII). Cumulative
distribution of differentially expressed mRNAs (FDR ≤ 0.20) with predicted targets of
miR-512, miR-520, miR-1323 and miR-515 (TargetScan, release 7.1) showed a
statistically significant (p ≤ 0.05) shift to the left, implying a dominant down-regulation of
its target genes in line with activation of the C19MC cistron (Figure 8 A-D).

C19MC target mRNAs are enriched in cell differentiation pathways
We focused on the 369 transcripts downregulated (FDR ≤ 0.20, ≤ -1.5 -fold) in both with
759-sgRNA/SAM and 620-sgRNA/SAM transfected HEK cells. Of these 369 mRNA
transcripts, 181 were predicted targets of C19MC (MirWalk 2.0 288) (Figure 9A).
Hallmark gene set analysis revealed that these 181 genes are significantly enriched in
the hedgehog signaling (HH), EMT, UV response, hypoxia and p53 pathways (FDR ≤
3.32x10-5) (Figure 9B). Surprisingly, RNAseq of HEK293 cells transiently transfected
with 620-gRNA/SAM or 759-gRNA/SAM also revealed 288- or 11-fold increase
respectively, (FDR ≤ 0.2) in the expression of FGF4, and a 12.9 -fold increase (FDR £
0.2) in OCT4 in759-gRNA/SAM transfected cells (Supplementary Table SII). The
expression of OCT4 and other pluripotency transcription factors SOX2 and NANOG
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were assessed by qRT-PCR which showed that OCT4 expression was > 8 -fold
increased (p < 0.05) in HEK293 cells transiently transfected with 759-gRNA/SAM but
not in 620-gRNA/SAM (Figure 9C).

C19MC inhibits the expression of EMT genes.
To further investigate the effect of C19MC overexpression on the EMT pathway,
we used the EMT RT2 profiler PCR Array (Qiagen) to quantify changes in the
expression of 84 EMT associated genes. The qRT-PCR array showed 2- to 4.75-fold
decrease in the expression of CDH2, SERPINE1, TWIST1, SNAI2, CALD1, GSC,
ITGAV, MMP3, TCF and WNT5a (p ≤ 0.05) in HEK293 cells transfected with 620sgRNA/SAM compared to control, confirming the hallmark gene set analysis (Figure
10). These data were further confirmed by qRT-PCR analysis that showed significant
decrease in the expression of CDH2, SERPINE1, TWIST1 and SNAI2 in HEK293 cells
transfected with 759-sgRNA/SAM or 620-sgRNA/SAM compared to control compared to
control (Figure 11 A). To determine if the decrease in the expression of CDH2 was as a
result of direct targeting by C19MC miRNAs, we constructed a luciferase reporter
containing the 3’ UTR of the CDH2 gene. HEK293 cells transfected with 759sgRNA/SAM and the CDH2 3’ UTR luciferase construct showed 35% decrease (p <
0.05) in luciferase activity (Figure 11B). Taken together, these results indicate that
overexpression of C19MC induces the transcription of major pluripotent factors OCT4
and FGF4 and inhibits EMT by directly repressing the expression of genes that are
crucial for EMT.
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Figure 5. C19MC expression in the human placenta. (A-B) Representative images of
in situ hybridization for scramble control or miR-517a/c (purple), nuclei counterstained
with red and double-immunostaining for trophoblast marker cytokeratin (brown) and
decidual marker vimentin (pink) of adjacent consecutively cut sections from first
trimester human placenta sections (A) or term placenta (B). Scale bar represents
400μm. Original magnification 10x, Black inserts 20X, pink and purple inserts 40X.
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A

B

Figure 6. Location of C19MC sgRNAs.
Location of the gRNA#759 (A) and gRNA#620 (B) relative to the upstream CpG island
(Green rectangle) and the first miRNAs of the C19MC cluster as viewed on the UCSC
Genome Browser screen.
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Figure 7. Transcriptional activation of C19MC. (A-B) Venn diagram of upregulated
miRNAs (A) and downregulated miRNAs (B) from sRNAseq data from 3 independent
experiments in HEK293 cells transfected with either 759-sgRNA/SAM or 620sgRNA/SAM for 72 hr. (C-D) qRT-PCR analysis of four representative miRNAs of the
C19MC cistron or miR-21 normalized to U18, 72h after transfection of HEK293 cells with
759-sgRNA/SAM or 620-sgRNA/SAM (C) or 72h after transfection of HTR8/SVneo cells
with 759-sgRNA/SAM (D). Graphs represent means ± SEM of at least 3 independent
experiments containing 3 replicates each. *p < 0.05 vs. GFP transfected control cells by
2-way ANOVA with Dunnett’s post-hoc (C) or by Multiple T-tests with Holm-Sidak
correction (D).
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Figure 8. C19MC downregulates predicted mRNA targets
(A-D) Cumulative distribution of differentially expressed mRNAs targeted by miR-512,
miR-520, miR-1323 and miR-515 in HEK293 cells transfected with 759-sgRNA/SAM
compared to GFP transfected cells compared to GFP transfected cells.
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Figure 9. C19MC targets mRNAs are enriched in cell differentiation pathways
(A and B) Venn diagram (A) and Hallmark gene set analysis (B) of the 181 common
downregulated mRNAs in HEK293 cells transfected with 759-sgRNA/SAM or 620sgRNA/SAM compared to GFP control and predicted C19MC miRNAs target genes. (C)
qRT-PCR analysis of the indicated genes normalized to GAPDH in HEK293 cells
transfected with 759-sgRNA/SAM for 72 hours. Graph represents means ± SEM of at
least 3 independent experiments containing 3 replicates each. * p < 0.05 vs. GFP
transfected control cells (multiple t-tests with Holm-Sidak correction).
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Figure 10. C19MC alters the EMT gene expression profile in HEK293 cells
Heatmap showing non-hierarchical clustering of EMT genes with dendograms indicating
co-regulated genes in 620-sgRNA/SAM transfected cells and GFP control.
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Figure 11. C19MC inhibits the expression of EMT genes
(A) qRT-PCR analysis of the indicated genes normalized to GAPDH in HEK293 cells
transfected with 759-sgRNA/SAM or 620-sgRNA/SAM for 72 hr (B) Luciferase reporter
assay of HEK293 cells transfected with 759-sgRNA/SAM and PGL2 basic plasmid
containing CDH2 3’ UTR normalized to GFP control. Graphs represent means ± SEM of
at least 3 independent experiments containing 3 replicates each. * p < 0.05 vs. GFP
transfected control cells. (A: Two-way ANOVA with Dunnett’s post-hoc, B: multiple t-tests
with Holm-Sidak correction)
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Hypoxia inhibits C19MC and increases the expression of EMT markers in iPSCs
During the first trimester, oxygen tension plays a key role in regulating
trophoblast cell proliferation and differentiation22, 289. To determine the effect of hypoxia
on C19MC expression in vitro and avoid the spontaneous differentiation that occurs in
primary human trophoblast cells290, we used iPSCs which share many stem like
characteristics with CTs and express similarly high levels of C19MC. sRNAseq analysis
of iPSCs exposed to hypoxia (1% O2) for 24 hours showed 1.9-fold decrease in the
expression of C19MC (mir-498 cistron), while the hypoxia-inducible miR-210291 was
13.9-fold increased (FDR ≤ 0.20) compared to normoxia conditions (21% O2) (Table 2).
Specifically, 12 miRNAs of the C19MC were 2.1- to 292.6-fold decreased FDR ≤ 0.20
(Supplementary Table SIII), of which five miRNA were confirmed by qRT-PCR (Figure
12A).
Hallmark gene set analysis revealed that hypoxia induced the expression of
genes involved in hypoxia response, EMT, and P53 pathways whereas E2F and G2M
checkpoint pathways were decreased (FDR £ 0.2) (Supplementary Table SIV).
RNAseq analysis showed 43.7- and 10-fold increase (FDR ≤ 0.20) in SERPINE1 and
TWIST1, respectively in iPSC exposed to hypoxia (Supplementary Table SIV). The
increase in the expression of the EMT genes, SERPINE1, TWIST1 and SNAI2 (18.6-,
1428.2-,4.7-fold, respectively, p<0.05), was also confirmed by qRT-PCR (Figure 12B).
Furthermore, qRT-PCR analysis of iPSCs exposed to hypoxia showed downregulation
of the stem cell associated genes LIN28A, LIN28B, SOX2, NANOG and OCT4 (Figure
12C).
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BMP4 mediated differentiation of iPSCs to CTs induces EMT and inhibits C19MC
Hypoxia is known to preferentially promote the initial differentiation of CTs into
EVTs263. To determine the effect of hypoxia on C19MC and EMT genes during the CT
to EVT differentiation process, we used a previously described method for iPSC
differentiation263. First, we differentiated iPSCs into CT (iPSC-CTs) using a low dose
BMP4 treatment (Figure 13A). Following BMP4 treatment, iPSC-CTs showed a more
flattened and elongated CT phenotype and expressed high levels of the CT associated
genes P63 and CDX2 compared to undifferentiated iPSCs (Figure 13B and C).
Moreover, iPSCs-derived CTs showed reduction in OCT4 expression compared to
undifferentiated iPSC (Figure 13C). Next, we sought to determine the expression of
C19MC and EMT genes during low-oxygen induced EVT differentiation. We re-plated
iPSC-CTs and continued to differentiate them in FCM supplemented with BMP4 under
normoxic or hypoxic conditions. In hypoxia, the cells expressed significantly reduced
levels of PSG4 (an STB-associated transcript) and showed significant increase in the
expression level of HLAG (an EVT marker) consistent with the observation that ST
differentiation is inhibited by low oxygen conditions290, 292 (Figure 13D). Interestingly,
iPSC-CTs, and iPSC-CTs further cultured in normoxia or hypoxia showed an increase in
the EMT genes CDH2 and SERPINE1 and loss of C19MC miRNAs miR-518c and miR519d compared to undifferentiated iPSCs (Figure 13E and F). This is likely due to the
use of BMP4, an EMT inducer, in the differentiation of iPSCs to CTs293-295. These data
show that EMT induced by hypoxia or BMP4 is associated with a significant decrease in
the expression of C19MC.

79

Table 2. Hypoxic conditions decrease expression of the C19MC cistron in iPSCs.
Data shows fold change of normalized frequency (>2- fold, FDR £ 0.2). C19MC.
Normalized frequency (%)
miRNA
cistron

Hypoxia

Normoxia

Fold change

FDR

mir-498(46)

0.342795

0.653611

-1.9

0.01078437

mir-30b(2)

0.683601

0.385398

1.8

0.12703533

mir-424(2)

0.108522

0.03614

3

0.00814663

mir-598(1)

0.0331

0.010923

3

0.10326634

mir-9-1(3)

0.381634

0.123784

3.1

0.01362189

mir-489(2)

0.012991

0.003859

3.4

0.16704579

mir-210(1)

0.412455

0.029741

13.9

1.34E-08
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Figure 12. Hypoxia inhibits C19MC and increases the expression of EMT markers
in iPSCs
(A-C) qRT-PCR analysis of the indicated miRNA normalized to U18 (A) or indicated
genes normalized to GAPDH (B and C) of iPSCs cultured in hypoxia (1% O2)
or normoxia (21% O2,) for 24 hours. Graphs represent means ± SEM of at least 3
independent experiments containing 3 replicates each. * p < 0.05 vs. normoxia control
cells. (A-C: Multiple t-tests with Holm-Sidak correction)
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Figure 13. BMP4 mediated differentiation of iPSCs to CTs induces EMT and
inhibits C19MC
(A and B) Schematic (A) and 20x phase images (B) showing two-step cytotrophoblast
differentiation using low dose BMP4. iPSCs were cultured in EMIM + 10 ng/ul BMP4 for
4 days to form flattened CTB like cells. Cells were replated and further cultured in FCM +
BMP4 for 4 days under normoxic and hypoxic conditions to induce STB and EVT
differentiation. (C-F) qRT-PCR analysis of the indicated genes normalized to GAPDH (CE) or the indicated miRNA normalized to U18 (F). Graphs represent means ± SEM of at
least 3 independent experiments containing 3 replicates each. * p < 0.05 vs. iPSC (C:
Multiple t-tests with Holm-Sidak correction, D-F: Two-way ANOVA with Dunnett’s posthoc).
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C19MC increases efficiency of somatic cell reprogramming
Since C19MC miRNAs are highly expressed in embryonic stem cells and
increased OCT4 expression, we tested whether C19MC miRNAs induce cell
reprogramming. Therefore, normal Human Dermal Fibroblasts cells (NHDFs) were
transfected with 759-sgRNA/SAM alone, with three episomal plasmids that contains
reprogramming factors OCT3/4, SOX2, KLF4, and LIN28 in combination with L-MYC
and p53 shRNA as previously described (Y4) 262, or with a combination of 759sgRNA/SAM and Y4 together (759-sgRNA/SAM + Y4) (Figure 14A).
In NHDFs transfected with 759-sgRNA/SAM only, no colonies were observed (Figure
14B). Intriguingly, NHDF cells transfected with 759-sgRNA/SAM +Y4 developed a
significantly higher number of colonies (an average of 17 colonies/200,000 cells)
compared to cells transfected with Y4 alone which developed an average of 5
colonies/200,000 cells (p ≤ 0.05) at day 24 post transfection (Figure 14B). Moreover,
the colonies were observed sooner in NHDFs cells transfected with 759-sgRNA/SAM
+Y4 at 7 to 10 days post transfection compared to 14 to 20 days post transfection in
cells transfected with Y4 alone (Figure 14C). The undifferentiated stage of the colonies
was confirmed by alkaline-phosphatase staining at day 24 post transfection (Figure
21D). These data indicate that combination of 759-sgRNA/SAM +Y4 increases the
speed and efficiency of cell reprogramming.
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Figure 14. C19MC increases efficiency of somatic cell reprogramming
(A) Schematic of transfection protocol. 759, sgRNA-759/SAM; Y4, Yamanaka factors. (B)
Colony counts from 759-, Y4- and 759+Y4-transfected NHDFs at day 24. (C) Colony
morphology at 10 days post transfection. (D) AP staining of iPSC clones from Y4- or
759+Y4-transfected NHDFs at day 24. Graph represents colony counts (B: ANOVA with
Dunnett’s post-hoc)

84

C19MC iPSCs form embryoid bodies in vitro and teratomas in vivo
To test the differentiation potential of iPSCs generated using 759-sgRNA/SAM
+Y4 in vitro, we used a floating cultivation method for embryoid body formation. iPSCs
generated using 759-sgRNA/SAM +Y4 formed spheroid shaped structures after 8 days
in suspension culture (Figure 15A). Embryoid bodies were transferred to gelatin-coated
plates and cultured for an additional 7 days. Attached cells showed various cell
morphologies including beating cardiac like cells (Supplemental video 1). We analyzed
the embryoid bodies for the expression of the germ layer markers ACTA2 (mesoderm),
TUBB3 (ectoderm) and GATA4 (endoderm) by qRT-PCR and found significantly higher
levels of ACTA2 and GATA4 (84- and 37- fold respectively, p£ 0.05) compared to
undifferentiated control iPSCs (Figure 15B).
In order to test the pluripotency of iPSCs generated using 759-sgRNA/SAM +Y4,
cells were transplanted subcutaneously into dorsal flanks of SCID immunodeficient
mice. Tumors were harvested four weeks after injection for histological analysis. Tumor
sections were immunostained with a human mitochondria specific antibody to
differentiate between implanted human cells and mouse cells and nuclei were
counterstained with hematoxylin. Histological examination showed that the tumor
contained various tissue structures derived from the three germ layers, endoderm,
mesoderm and ectoderm (Figure 15C-E).
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Figure 15. C19MC iPSCs form embryoid bodies in vitro and teratomas in vivo
(A) Image of embryoid bodies at 7 days in suspension cell culture. (B) qRT-PCR
analysis of 3 germ layer markers in embryoid bodies compared to non-differentiated
human iPS cells (clone 3-CF-6 P5). (C-E) Images of hematoxylin stained teratoma
sections showing ectoderm, mesoderm and endoderm like cellular structures. Graph
represents means ± SEM. * p < 0.05 (Multiple t-tests with Holm-Sidak correction)
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Discussion
Trophoblast differentiation and subsequent invasion into the decidua is critical for
implantation and placentation during early pregnancy. Villous trophoblasts (VTs)
possess epithelial characteristics with apicobasal polarity, lateral cell junctions and
basal contact with basement membrane27. Upon differentiation to EVTs, they undergo
EMT and lose their cell junctions and apical basal polarity and acquire migratory and
invasive capacity27. This study demonstrates that C19MC is primarily expressed in the
non-invasive epithelial VTs and is lost as trophoblast differentiate into EVTs. Utilizing
the CRISPR SAM system we were able to transcriptionally activate the entire
endogenous C19MC and demonstrate its role in enhancing the epithelial stem cell state.
Co-expression of C19MC miRNAs with Yamanaka factors (C19MC+Y4) in NHDFs
significantly increases the efficiency of reprogramming to iPSCs. While under hypoxic
condition, the expression of C19MC is reduced, which in turn induces EMT and cell
differentiation.
To our knowledge, this is the first report that shows the in-situ expression of one
miRNA of the C19MC cistron in first trimester human placental tissues. These images
reveal that C19MC is highly expressed in the VTs comprising of CTs, STs and in the
proliferative (proximal) trophoblastic cell columns in the anchoring villi. C19MC
expression is gradually lost as trophoblast differentiate into EVT and is not expressed in
the decidual layer of the placenta. These data are in agreement with previous report
that utilized laser-capture microdissection of paraffin-embedded placental specimens
followed by RT-qPCR105.
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To investigate the role of C19MC in trophoblast differentiation, we employed a
new strategy to transcriptionally activate the whole C19MC cluster that span over 100
kb. Until recently, studying the functions of C19MC miRNAs has been challenging
because of its size. Several groups have used the Bacterial Artificial Chromosome
(BAC) technology, which carries the entire C19MC locus within its chromatin and all the
regulatory elements (CpG islands, promoters, Alu repeats, enhancers, silencers,
insulators etc.296) which resulted in modest upregulation of some miRNAs of the
C19MC105, 110. Furthermore, the construction, screening, transfection and selection for
stable integration of BAC plasmids are time and labor intensive. Other groups have
used miRNA mimics to over express some C19MC miRNAs but using this method to
upregulate all 56 mature miRNAs is not feasible. In this study we used CRISPR SAM
technology to transcriptionally activate the entire C19MC cistron. To avoid the imprinted
upstream CpG island97 we designed guide RNAs to bind only a few hundred base pairs
upstream of the first miRNA genes. Comparing sRNAseq analysis of three independent
experiments using either 759-sgRNA/SAM or 620-sgRNA/SAM in HEK293 cells
revealed that a single guide RNA is sufficient to upregulate the expression of the entire
100 kb C19MC locus. This transcriptional activation is specific to C19MC as the
expression of the neighboring miR-371-373 cluster, which is located 20 kb downstream
of the C19MC, was not increased, supporting a previous report that C19MC miRNAs
are a product of a single transcript that gets rapidly spliced and then processed by
Drosha-DGCR8 complex 93. Only two upregulated miRNAs that are not member of the
C19MC overlapped in the 3 independent experiments, miR-139 and miR-449.
Interestingly, these two miRNAs are known to be inhibitors of EMT and may be
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regulated by the C19MC297, 298. Some other miRNAs that are known to stimulate cell
reprogramming and do not belong to the C19MC were also upregulated in HEK293 cells
transfected with either 759-sgRNA/SAM or 620-sgRNA/SAM. On the other hand, some
miRNA that are known to promote cell differentiation including let-7a, miR-34a, miR181b, miR-15a, miR-15b, miR-133a, miR-29b and miR-205, were downregulated.
However, no overlap in the dowregulated miRNAs was observed in the three different
experiments. These non-C19MC miRNAs may be directly or indirectly regulated by the
C19MC. Further studies are needed to investigate the potential crosstalk between
C19MC and the other differentially expressed miRNAs. Therefore, in the present study
we were able to activate the entire C19MC locus in different human cell lines in a highly
efficient, specific, and reproducible manner. This new approach provides a powerful
tool for studying the contribution of C19MC miRNAs during pregnancy.
In agreement with the physiological expression of C19MC miRNAs in VTs and its
gradual loss in EVTs, we found that transcriptional activation of the C19MC led to
significant decrease in the expression of numerous genes involved in HH signaling and
EMT, many of which are C19MC predicted targets. This data is in agreements with
previous study which showed that overexpression of C19MC in an EVT cell line, HTR8SVneo, decreases migration105. Moreover, numerus studies have shown a link between
HH signaling and EMT 299. In human trophoblast, activation of HH signaling induced key
EMT regulators including SNAI1 and TWIST1 300. Therefore, the data presented here
place C19MC upstream of HH and EMT signaling, suggesting that the high levels of
C19MC in the villous trophoblasts maintain their stem-like epithelial phenotype and
suppress HH and EMT. Whereas, loss of C19MC release the inhibition on the HH and
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EMT genes which leads to acquisition of the migratory and invasive characteristics of
EVTs. Several studies have shown increased expression of miRNAs of the C19MC in
placenta and maternal serum of PE affected pregnancies 116, 301. Other studies showed
down-regulation of EMT genes correlates with preeclampsia302-305. Therefore,
maintaining optimal expression levels of C19MC may be critical for EVT differentiation
and invasion and dysregulation in C19MC may result in preeclampsia or placenta
accreta.
This study reveals that transient activation of C19MC increased the expression of
FGF4, which is essential for mammalian embryogenesis. Until now, FGF4 was known to
be secreted from the inner cell mass in a paracrine fashion and stimulate the growth
and proliferation of trophectoderm during early blastocyst development 4. The increase
in FGF4 by C19MC in HEK293 cells described here is very significant because it
suggests that VTs that express high levels of C19MC, may also express FGF4 and
provide optimal signaling during embryonic development. We also show that activation
of C19MC increased OCT4 expression, in agreement with previous study that used a
lentiviral vector encoding mir-524 precursor, a member of the C19MC287. The
mechanisms by which C19MC induce the expression of OCT4 and FGF4 is not yet
clear. It might be due to inhibition of transcriptional suppressors or by binding to the
promoter regions and inducing gene expression306, 307. Further studies are needed to
determine the mechanism by which C19MC increase the expression of OCT4 and
FGF4.
Transient expression of C19MC and Y4 resulted in a significant increase in the
number of iPSC colonies that formed embryoid bodies and teratomas, whereas
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activation of C19MC alone was unable to do so. Activation of C19MC using the
CRISPR/SAM approach exerted a profound inhibition of genes involved in the p53
pathway in addition to the HH signaling and EMT. These data are in agreement with
previous studies showed that suppression of the p53 pathway increased the efficiency
of human iPSC generation308. Moreover, some miRNAs of the C19MC share the same
seed sequences with miRNAs of the miR-302/-372 families which have been shown to
enhance reprogramming by promoting MET286. Lentiviral vector encoding mir-524
precursor was also unable to reprogram the normal fibroblast cells, however, when coinfected with OSKM factors-encoding lentiviruses, it enhanced the reprogramming
process287. The findings of the present study suggest that expression of high levels of
C19MC in VT may play an important role in sustaining a stem cell environment to
support the placentation and thereby the developing fetus.
The early placental environment is very hypoxic as intervillous circulation is not
established until after the first trimester22, 289. EVTs migration, invasion into the maternal
decidua and remodeling of the maternal spiral arteries are important steps for proper
perfusion of the placenta, which is necessary for a successful pregnancy27. Changes in
oxygen tension within the inter-villous space are stringently controlled and play a role in
trophoblast differentiation, migration and invasion that are necessary for vascular
remodeling during pregnancy309. The present study shows that at the top five gene set
analysis targeted by C19MC cistron are genes that are normally up-regulated in
response to hypoxia. These data suggest that by expressing high levels of C19MC, VTs
become more tolerant to hypoxia. Previous work has used primary human trophoblast
(PHT) cells to test the effect of hypoxia (<1% oxygen) on C19MC expression. However,
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PHT cells underwent spontaneous differentiation when cultured in vitro over 72 hours
and the expression levels of C19MC miRNA were not reliably detectable284. Therefore,
it is not possible to determine the effects of hypoxia on C19MC using PHT cells. Since
CTs share many stem cell-like characteristics and to avoid the spontaneous
differentiation of PHTs, in this study we used undifferentiated iPSCs and found that 24hr
exposure to hypoxia (1% oxygen) significantly decrease in the expression of different
miRNAs of the C19MC and several reprogramming factors, while the expression of
EMT related genes were increased. These results are in line with previous studies that
reported that hypoxia is a major inducer of EMT310-312. Hypoxic conditions also
decreased the expression of OCT4 in agreement with studies that show that repression
of OCT4 induces loss of pluripotency and dedifferentiation of ESC cells derived from the
inner cell mass toward the trophectoderm313.
The data presented here suggest that hypoxic conditions during early
placentation reduce C19MC expression and induce EMT and differentiation of CTs into
EVT. The mechanism by which hypoxia reduces the expression of C19MC miRNA are
not yet known. De novo methylation may be one potential mechanism. In fact, previous
study has shown that tumor hypoxia reduced the activity of oxygen-dependent teneleven translocation (TET) enzymes that catalyze DNA demethylation of tumor
suppressor genes314. Hypoxia may also regulate C19MC miRNA biogenesis and
activity315. Further studies are needed to elucidate the mechanisms by which hypoxia
reduce C19MC expression.
We also show that the expression levels of miRNA of the C19MC cistron were
significantly reduced when iPSCs were differentiated into bipotential stem-like CTs and
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when these cells were subsequently terminally differentiated into STs and EVTs.
Furthermore, EMT genes SERPINE1 and CDH2 were increased at both stages of
differentiation. Although the decrease in C19MC miRNAs and increase in EMT genes in
iPSC-CTs was unexpected, it is consistent with the induction of EMT by BMP4 used in
the differentiation protocol. BMP4 has been shown to promote EMT and mesodermal
commitment in stem cells, induce EMT in ovarian cancer cells, and induce an EMT-like
response in C3H10T1/2 pluripotent stem cells293-295, 313. Since C19MC is highly
expressed in normal human trophoblasts It is notable that the iPSC-CTs we generated
showed reduced expression of C19MC105. This data indicates that trophoblasts
generated using this protocol are atypical as they do not fully recapitulate the gene
expression profile of normal trophoblasts. This limitation can affect the utility of these
cells for downstream studies. These results therefore suggest that downregulation of
C19MC is strongly associated with the induction of EMT by hypoxia or other means
such as low dose BMP4 treatment. Although our data shows a strong association
between C19MC and EMT, C19MC knockdown experiments in epithelial cells are
required to prove that C19MC regulates EMT. However, due to the size of the cluster,
we have not been able to successfully knock down its expression in vitro.
Taken together, the data presented in this study establish the utility of
CRISPR/SAM technique as a powerful tool to investigate the role of C19MC in physiology
of human placental. Employing this robust technique enabled us to uncover the crucial
role of C19MC in maintaining CTs multipotency and shows that loss of C19MC is required
for EMT transition of trophoblast to gain invasive phenotype.
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Chapter 7
Modulation of LIN28B/Let-7 Signaling by Propranolol Contributes to Infantile
Hemangioma Involution
Introduction
Infantile hemangiomas (IH) are highly vascularized benign tumors diagnosed in 3-10%
of children before they are one year old316. IH lesions have a unique pattern of growth in
which the initial phase of rapid proliferation is followed by slow spontaneous involution
that leaves behind a fibro-fatty residuum221. During the proliferative phase, immature
endothelial cells, positive for glucose transporter-1 (GLUT1), form aberrant blood
vessels, rich in α-smooth muscle actin-positive pericytes and mast cells194. This
endothelial GLUT1 expression distinguishes IH from other types of vascular tumors and
vascular malformations198, 317. Stem cell reprograming factors OCT4, SOX2 , NANOG
and MYC are also highly expressed in IH318.
The chromosome 19 microRNA (miRNA) cluster (C19MC), referred to as miRNA
cistron mir-498(46) or mir-498(46), was recently reported to be highly expressed in
IH119. Mir-498(46) is unique to primates and is the largest known human miRNA gene
cluster that spans over 100 kb and contains 46 miRNA genes flanked by Alu
elements283. Expression of miRNA genes in this cluster is restricted to the placenta,
embryonic stem cell (ESC) and certain tumors121, 122, 283, 319.
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While some studies have shown considerable similarity between IH and placental
transcriptomes200, which suggests a placental origin for proliferating cells in IH199, other
studies propose that IH originate from hemangioma stem cells204. In support of the latter
notion, human CD133+ hemangioma stem cells (HemSCs) implanted subcutaneously
into immunodeficient mice induce GLUT1-positive microvessels, which are gradually
replaced by adipocytes, thereby reproducing the IH involution phase. Importantly, when
grown in culture, GLUT1-positive/mir-498(46)-expressing endothelial cells, isolated from
proliferative IH, lose the expression of mir-498(46) and GLUT1 and undergo an
endothelial-mesenchymal transition (EndMT), a process similar to epithelialmesenchymal transition (EMT)119, 320.
Serendipitously, it was discovered by Léauté-Labrèze that the non-selective
beta-adrenergic receptor blocker, propranolol, triggers early involution of IH236.
Consequently, propranolol has become the first line therapy for IH238. Previous work has
shown that propranolol-treated IH tumors contain significantly lower levels of mir498(46) than proliferative IH119. Moreover, levels of circulating mir-498(46) fall during
the involution phase and correlate with the clinical response to propranolol treatment119,
suggesting the potential involvement of mir-498(46) in the pathogenesis of IH.
The self-renewal capacity of ESCs is regulated in part by a set of interactive
gene products, LIN28 and the let-7 family of miRNAs. Two human LIN28 paralogs,
LIN28A and LIN28B, are highly expressed in ESCs. They inhibit the post-transcriptional
maturation of let-7 miRNAs and influence mRNA translation140, 142. Conversely, let-7
negatively regulates the expression of LIN28 by interacting with the 3’ untranslated
regions of both LIN28A and LIN28B mRNAs136. This interaction creates a double
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negative feedback loop, which is highly conserved. Ectopic expression of LIN28A or
LIN28B alongside the reprogramming factors Oct4, Sox2, and Nanog157, 165, 166 has
been successfully used to generate induced pluripotent stem cells (iPSCs) from
fibroblasts. In addition, LIN28B overexpression has been successfully used to generate
iPSCs from fibroblasts24.
EMT is the biological process through which normally polarized epithelial cells
lose their apical-basal polarity and acquire a mesenchymal cell phenotype characterized
by enhanced migration and invasiveness, resistance to apoptosis and increased
deposition of extracellular matrix components24. This trans-differentiation is mediated by
key transcription factors such as SNAIL, SLUG, TWIST1 and ZEB that regulate
downstream epithelial markers, which among other effects, leads to decreased Ecadherin levels and increased expression of mesenchymal cell markers, such as Ncadherin and vimentin279. iPSC generation from fibroblasts requires suppression of EMT
and activation of mesenchymal-epithelial transition (MET) signals37.
IH represents a unique model to study postnatal vasculogenesis and vessel
regression. Despite the prevalence of these tumors, the complex pathogenesis of IH is
poorly understood. Given the role of LIN28/let-7 axis in governing stem cell self-renewal
and cell differentiation, we hypothesized that LIN28/let-7 signaling is dysregulated in IH.
In this study, we demonstrate that LIN28B is highly expressed in proliferative IH
samples and is downregulated both in involuted and propranolol-treated IH samples.
Consistent with those observations, in vitro treatment of iPSCs with propranolol caused
a decrease in LIN28B, mir-498(46) expression, decreased cell proliferation and
increased the expression of let-7 family of miRNAs and EMT genes. Our results
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highlight the role of LIN28 and let-7 in the pathogenesis of IH and offers a new
mechanism by which propranolol induces involution of IH.

Results
LIN28B is highly expressed in proliferative IH
IH are derived from dysregulated stem cells321 and represent a unique tumor
model characterized by a proliferative phase followed by spontaneous involution,
regulated by yet unknown mechanisms. Given the key role of the LIN28/let-7 axis in
governing stem cell self-renewal and cell differentiation, the expression levels of LIN28A
and LIN28B were first assessed in IH samples by qRT-PCR and compared to normal
infant skin (NS) and samples of normal human placentas at term. IH samples exhibited
a 7- and 7500-fold increase (p < 0.05) in LIN28A and LIN28B, respectively, compared to
NS (Figure 16A). The expression levels of LIN28A and LIN28B in IH were comparable
to their expression levels in the placenta (Figure 16A).
Given the dramatic increase of LIN28B expression in IH, all subsequent experiments
were focused on LIN28B. To determine if LIN28B is differentially expressed in
proliferative IH compared to involuting/involuted IH, we assessed LIN28B expression by
qRT-PCR and found that it was 2.7-fold higher (p < 0.33) in proliferative compared to
involuting/involuted IH samples (Figure 16B).
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Figure 16. LIN28B is highly expressed in proliferative IH.
A, B, Quantitative RT (qRT) PCR analysis of LIN28A and LIN28B (A) or LIN28B (B)
expression normalized to GAPDH. IH (n=4), normal skin (NS; n=4), normal term
placenta (PL, n=4), proliferative IH (n=2), and involuting/involuted IH (n=2). Graphs
represent means ±SEM. *P<0.05 vs NS (A), vs involuting/involuted IH (B) by one-way
ANOVA with Dunnett post hoc test (A) or 2-tailed Student t test (B).
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LIN28B is highly expressed in proliferative IH sections and is reduced upon involution
To determine LIN28B cellular localization, dual immunofluorescence staining for
LIN28B and the IH marker, GLUT1, was performed in paraffin embedded IH sections
obtained from proliferative and involuted IH specimens. Term placenta samples were
used as positive controls. In proliferative IH samples, LIN28B was highly expressed and
co-localized with the GLUT1 positive endothelial cells as well as perivascular nonendothelial cells, whereas involuted IH samples showed weak staining for both LIN28B
and GLUT1 (Figure 17 A). As expected, in term placentas LIN28B and GLUT1 were colocalized in trophoblast and endothelium of chorionic villi (Figure 17A). Quantifications
of LIN28B to GLUT1 immunofluorescence signal intensities showed ~2-fold increase in
proliferative IH compared to involuted IH samples (Figure 17B). These data confirm the
increased expression of LIN28B in proliferative IH and its localization in GLUT1-positive
endothelial cells and perivascular non-endothelial cells that may display properties of
facultative stem cells320.
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Figure 17. LIN28B is highly expressed in proliferative IH sections and is reduced
upon involution.
A, Representative immunostaining for LIN28B and GLUT1 (glucose transporter-1) of
proliferative IH (n=4), involuting/involuted IH (n=5) and term placenta (n=3) samples.
Nuclei were counterstained with DAPI. No positive immunostaining was observed in the
negative control sections (Alexa Fluor 488 or cy3). Scale bars: 50 μm; original
magnification, ×60 and ×120 (insets). B, Quantification of LIN28B/GLUT1 fluorescence
signal ratio in proliferative and involuted IH samples. Graph represents means±SEM.
*P<0.05 vs involuted IH (D) tailed Student t test.
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Let 7 miRNAs are downregulated in IH
The let-7 miRNA family and numerous other miRNAs negatively regulate LIN28B
by binding to its 3'UTR (Figure 18A). To determine whether the increase in LIN28B in
IH samples is associated with decreased expression of these miRNAs, small RNA
sequencing (sRNAseq) analysis was performed on eight IH and five NS samples.
Looking at the most abundant, or highly expressed, miRNAs (i.e. consuming the top
90% of sequencing reads) in IH compared to NS samples showed 32 significantly
changed miRNA cistrons (FDR 0.25), of which 21 were upregulated in IH and 11
downregulated in IH compared to NS (Table 3). Of the 21 upregulated miRNA cistrons,
mir-498(46) was most extensively upregulated with a 492-fold increase (Table 3). The
downregulated cistrons include miRNAs that are predicted to bind to LIN28B 3'UTR,
namely let-7a, let-7c, let-7f, let-7g, let-7i, miR-19b(2), miR-506(1), miR-196a/b, miR455-5p(1), miR-9(3), miR-124(3), miR-27a(1), miR-27b(1), miR-23b(1), miR-125b(2),
miR-199b-5p(1), miR-19a(1) and miR-148a(1), which were 2- to 45.6-fold
downregulated (Supplementary Table SI). Importantly, let-7, miR-196 and miR-9 bind
to multiple target sites on LIN28B 3' UTR (Figure 18A). These data indicate that the
upregulation of LIN28B in IH may be due, at least in part, to its decreased posttranscriptional regulation by miRNAs. Additionally, LIN28B is an established repressor
of miRNA biogenesis147, among which let-7 is the most extensively studied141.
Consequently, sRNAseq analysis of IH and NS revealed that let-7g(1), let-7c(1), and
miR-200c(1) were 2.9-, 3.6- and 135-fold downregulated, respectively, in IH compared
to NS (Supplementary Table SI). To determine whether additional members of the let7 family were affected, yet did not pass the sRNAseq analysis filters, qRT-PCR analysis
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was performed for randomly selected members let-7a and let-7c. As expected, both
were downregulated (p <0.05) in IH compared to NS (Figure 18B).

LIN28B activates miR-498(46) miRNAs independently of the upstream CpG-island
The expression of mir-498(46) is controlled by methylation of an upstream CpGrich promoter region that includes a transcription start site located ~17 kb upstream of
the first miRNA gene97. To test whether the increase in mir-498(46) expression found in
IH samples is due to transcriptional activation of the upstream CpG-rich island, we
performed qRT-PCR using primer sets designed to amplify regions downstream of the
CpG-island, as previously described97. The trophoblast-derived choriocarcinoma BeWo
cell line, which endogenously expresses mir-498(46), was used as a positive control. IH
samples and BeWo cells displayed active transcription starting at the ~17kb upstream
mir-498(46) CpG-related promoter region, whereas no transcripts were found in NS
samples (Figure 19A). This indicates that the promoter region upstream of mir-498(46)
is transcriptionally active in IH.
Given that LIN28B expression is 7000-fold higher in IH than NS, we tested for a
possible positive regulation of mir-498(46) miRNAs by LIN28B. To that end, HEK293
cells were transiently transfected with a LIN28B-coding plasmid, and the expression
levels of LIN28B and of six randomly selected miRNAs of mir-498(46) miRNAs were
measured after 72 h by immunoblotting and qRT-PCR, respectively. Interestingly,
overexpression of LIN28B enhanced the expression of miR-516b by more than 2.6-fold
(p < 0.05) but did not significantly alter the expression of miR-515-5p, miR-516a-5p,
miR-517a, miR-518c and miR-519d (Figure 19B).
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To test whether LIN28B affects the methylation of the ~17kb CpG- island
upstream of mir-498(46) which activates its transcription, we performed an HpaIIsensitivity assay followed by qPCR. Overexpression of LIN28B did not induce a
significant increase in HpaII sensitivity of the CpG island (Figure 19C) or induce
transcriptional activation downstream of the CpG island (Figure 19D). These data
indicate that LIN28B induces the expression of mir-498(46) independently of the ~17kb
upstream promoter region.

Propranolol inhibits LIN28B in IH
The standard of care propranolol treatment of patients with IH induces rapid IH
involution. To determine whether propranolol affects the expression of LIN28B in IH, we
performed dual immunofluorescence staining of LIN28B and the IH marker, GLUT1, in
paraffin embedded IH sections obtained from propranolol-treated proliferative IH and
compared them to untreated proliferative IH samples. Both LIN28B and GLUT1 were
markedly decreased in propranolol-treated proliferative IH compared to untreated
proliferative IH (Figure 20A). In addition, quantification of LIN28B to GLUT1
immunofluorescence signal intensities showed ~2-fold increase in proliferative IH
compared to propranolol treated IH samples (Figure 20B).
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Table 3. Expression differences of highly expressed miRNA cistrons in IH vs. NS
by sRNAseq. Highly expressed cistrons were defined as being within the top 90%
RNAseq reads in any of the 8 IH and 5 NS samples. Shown are cistrons with a false
discovery rate of less than 25% in the differential analysis.
Cistron
(mir-)
498(46)
195(2)
378(1)
140(1)
30a(4)
10b(1)
15a(4)
142(1)
29a(4)
181a-1(4)
424(2)
26a-1(2)
22(1)
144(2)
143(2)
21(1)
26b(1)
191(2)
126(1)
30b(2)
25(3)
135a-1(3)
17(12)
130a(1)
199b(1)
148a(1)
221(2)
210(1)
141(2)
200a(3)
203(1)
205(1)

Normalized frequency (%)
Infantile
Normal
hemangioma
skin
8.888
0.018
2.312
0.543
3.760
0.899
1.079
0.279
5.075
1.473
2.428
0.724
1.576
0.523
0.536
0.195
1.902
0.698
1.570
0.596
3.495
1.437
9.431
3.934
3.401
1.420
3.972
1.679
18.461
9.717
4.601
2.758
1.467
0.901
0.675
0.438
1.724
1.103
0.970
0.640
0.988
0.706
0.764
1.097
1.145
1.754
0.299
0.501
0.785
1.437
0.993
4.427
0.226
1.130
0.025
0.376
0.049
1.947
0.010
0.553
0.014
6.200
0.013
1.730

Fold
change
492.7
4.3
4.2
3.9
3.4
3.4
3.0
2.8
2.7
2.6
2.4
2.4
2.4
2.4
1.9
1.7
1.6
1.5
1.6
1.5
1.4
-1.4
-1.5
-1.7
-1.8
-4.5
-5.0
-14.9
-40.8
-58.5
-461.0
-150.3

P Value
3.99E-12
3.65E-05
1.25E-05
1.76E-04
9.02E-05
5.04E-02
7.01E-03
9.35E-03
3.17E-02
7.35E-04
3.05E-03
1.94E-02
1.30E-02
6.92E-02
8.68E-02
3.72E-02
7.79E-02
1.17E-02
8.90E-02
6.42E-02
8.19E-02
7.29E-02
4.18E-02
3.72E-02
2.66E-02
1.39E-06
2.08E-09
1.40E-08
6.17E-06
6.34E-08
1.69E-10
1.14E-07

FDR
1.27E-09
4.29E-04
1.80E-04
1.66E-03
9.22E-04
1.49E-01
3.27E-02
4.11E-02
1.06E-01
5.98E-03
1.90E-02
7.49E-02
5.43E-02
1.91E-01
2.24E-01
1.22E-01
2.06E-01
4.99E-02
2.27E-01
1.80E-01
2.13E-01
1.96E-01
1.32E-01
1.22E-01
9.59E-02
2.45E-05
1.65E-07
6.34E-07
9.31E-05
1.78E-06
7.56E-09
2.59E-06
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Figure 18. Let-7 miRNAs are downregulated in IH.
A, Predicted miRNAs target sites in LIN28B 3′ untranslated region (UTR; TargetScan
Human Release 7.1). In red, downregulated miRNA in sRNAseq analysis of IH vs
NS. B, qRT-PCR analysis of let-7a and let-7c expression in IH (n=4) and NS (n=4).
Graph represent means ± SEM. *P<0.05 vs NS (B), by 2-tailed Student t test.

105

Figure 19. LIN28B activates mir-498(46) miRNAs independently of the upstream
CpG-island
A, RT-PCR analysis using P0, P1, P5, P8, and P9 primer sets reveals the presence of
transcripts generated upstream of mir-498(46) in infantile hemangioma (IH; n=4) but not
in normal skin (NS). BeWo cells were used as positive control and H2B as reference
gene. B–D, HEK293 cells were transfected with FLAG-LIN28B or GFP control vector for
72 hours followed by (B) qRT-PCR analysis of six randomly selected miRNAs of the
mir-498(46) cistron normalized to U18. Inset, representative immunoblot of LIN28B and
GAPDH; (C) HPAII sensitivity assay of the mir-498(46) cistron CpG island promoter
region and (D) RT-PCR analysis as described in A. Data represents means±SEM of 3
independent experiments. *P<0.05 vs GFP transfected cells by Mann–Whitney U test.
M indicates molecular marker.
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Figure 20. Propranolol inhibits LIN28B in IH.
A, Representative immunostaining for LIN28B and GLUT1 (glucose transporter-1) of
proliferative IH (n=4) and propranolol-treated proliferating IH (n=4) samples. Nuclei were
counterstained with DAPI. No positive staining was observed in the negative control
sections (Alexa Fluor 488 or Cy3). Scale bars: 50 μm; original magnification, ×60 and
×120 (insets). B, Quantification of LIN28B/GLUT1 fluorescence signal ratio in
proliferative and propranolol-treated samples. Data represent the mean ± SEM of at
least 3 independent experiments. *P<0.05 vs proliferative IH (B) by Student t test.
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Propranolol inhibits LIN28B in iPSCs
To further investigate the effects of propranolol on the expression of LIN28B and
let-7 in IH, we used the CD133+ HemSCs, which form hemangioma-like tumors when
injected subcutaneously in immunodeficient mice204. First, we tested whether HemSCs
express LIN28B and the miR-498(46) cluster in NS and IH. We also tested their
expression in BeWo cells and iPSCs, which are known to express high levels of both.
As negative controls, we used HUVECs that express neither LIN28B nor miR-498(46).
Surprisingly, qRT-PCR revealed that compared to NS, LIN28B showed only a 2-fold
increase in HemSCs, whereas in IH, iPSCs and BeWo cells LIN28B was >1000-fold (p<
0.05) higher (Figure 21A). As expected, negligible LIN28B expression was found in
HUVECs (Figure 21A). Moreover, sRNAseq analysis revealed that miR-498(46)
expression levels were 3.1-, 4.1-, 28- and 492.7- fold higher in HemSCs, HUVECs,
iPSCs and IH, respectively, compared to NS (Supplementary Table SI). Lastly, the
expression of LIN28B protein in HemSC and iPSCs was also assessed by Western blot
analysis, which showed negligible levels of LIN28B in HemSCs (Figure 21B). Based on
these findings, we proceeded to test the effect of propranolol in iPSCs, that express
LIN28B, miR498(46) and beta-adrenergic receptors. After propranolol treatment for 72
h, iPSCs showed a 2.3-fold decrease (p<0.05) in LIN28B protein levels (Figure 21C),
but no significant differences were found at the mRNA levels (data not shown).

Propranolol induces miR-98(13) and suppresses miR-498(46) in iPSCs
To further investigate the effects of propranolol on the expression of mir-498(46)
and let-7, iPSCs were treated with propranolol for 72 h and sRNAseq analysis was
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performed. Compared to vehicle control, propranolol treated-iPSCs showed a 3.2-fold
increase in the expression of cistron mir-98(13), which encodes 9 of 12 let-7 family
miRNA genes, and a 1.6-fold downregulation of mir-498(46) (Table 4). The results
were confirmed by qRT-PCR, which revealed significant reduction of mir-498(46)
members miR-515-5p, miR-517a, miR-518C and miR-519d and >1. 65-fold increase in
let-7a expression in iPSCs treated with propranolol for 72 hr (Figure 22A).

Propranolol induces EMT markers in iPSCs
Propranolol has been shown to induce early involution of IH, during which
immature vascular endothelial cells undergo EndMT, transitioning to a mesenchymal
phenotype with subsequent differentiation into adipocytes320. To test whether
propranolol induces the expression of mesenchymal markers, we performed mRNA
sequencing (RNAseq) on the same propranolol and vehicle treated-iPSC samples that
were used for sRNAseq. Gene set enrichment analysis performed on RNAseq data
showed an enrichment of genes defining EMT (FDR 0.00046) in propranolol treated iPS
cells compared to control (Supplementary Table S II). Gene set analysis also showed
upregulation of the pathways for adipogenesis and TGF-β signaling (FDR 0.09 and 0.06
respectively, Supplementary Table SII). Among the most highly upregulated genes,
two mesenchymal cell markers, SERPINE1 and TWIST1, showed a 12- and 2.9-fold
increase (FDR 1.06 x 10-6 and 0.004), respectively (Supplementary Table SII).
Upregulation of SERPINE1 and TWIST1 was further confirmed by qRT-PCR, which
showed 8.4- and 5-fold increased expression (p<0.05), respectively (Figure 22B).
Furthermore, gene set analysis of the RNAseq data also showed downregulation of E2F
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targets, G2M checkpoint and mitotic spindle pathways (FDR<0.25, Supplementary
Table SIII). We also examined propranolol-treated iPSCs for EMT associated
morphological changes and observed that propranolol treated iPSCs exhibited a more
elongated cellular shape compared to control (Figure 22C and D). Next, we tested the
effect of propranolol on iPSC proliferation using the WST1 proliferation assay.
Propranolol treatment induced a 33% decrease in cell proliferation without affecting cell
viability (Figure 22E and F). Furthermore, gene set enrichment analysis also showed
that E2F target genes and genes involved in G2/M cell cycle progression are
downregulated by propranolol treatment in iPSCs (FDR 0.006 and 0.017 respectively,
Supplementary Table SII) indicating that propranolol strongly inhibits proliferation.
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Figure 21. Propranolol inhibits LIN28B in iPSC.
A, Quantitative RT (qRT) PCR analysis of LIN28B expression normalized to GAPDH in
IH, iPSC, HemSC (line H42, from 3 independent passages), HUVEC, and BeWo cells
compared with normal skin (NS). B, C, Representative immunoblot for LIN28B and
GAPDH expression in (D) iPSC and HemSC line H42, from 3 independent passages
and (E) iPSCs treated with 50 μmol/L propranolol or vehicle control for 72 hours
accompanied by densitometric quantification of LIN28B normalized to GAPDH. Data
represent the mean±SEM of at least 3 independent experiments. *P<0.05 vs NS (A), vs
iPSCs (B), or vs vehicle control (C) by Student t test (B and C) or by one-way ANOVA
with Dunnett post hoc test (A).
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Table 4. Propranolol treatment decreases miR-498(46) expression and increases
let-7 miRNA expression in iPSCs. Shown are all cistrons with and FDR < 25%. In bold
mir-498(46) and mir-98(13).
Normalized
frequency (%)
Cistron
(mir-)
1226(1)
33b(1)
488(1)
498(46)
21(1)
188(8)
98(13)
10b(1)
10a(1)
3155(1)

Propranolol
0
0.002
0.0022
0.4075
10.5844
0.1459
0.2313
0.0176
0.0168
0.0014

Control
0.0029
0.0087
0.0082
0.6333
6.864
0.0842
0.0836
0.0024
0.0001
0

Fold
change
-579.2
-4.3
-3.8
-1.6
1.5
1.7
2.8
7.5
120.8
284.3

P
Value
0.0004
0.0094
0.0024
0.0021
0.002
0.0063
0.0074
0.0086
0.0018
0.0086

FDR
0.0994
0.2276
0.1167
0.1167
0.1167
0.2276
0.2276
0.2276
0.1167
0.2276
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Figure 22. Propranolol decreases the expression of mir-498(46) cistron and
induces let-7 and EMT genes in iPSCs.
iPSCs were treated with 50 μmol/L propranolol or vehicle control for 72 hours. A, B,
Quantitative RT (qRT) PCR analysis of indicated miRNAs or genes normalized to U18
or GAPDH, respectively. C, D, Representative ×40 bright-field images of control and
propranolol-treated iPSCs. E, F, Proliferation assay and representative fluorescence
microscopy images of Calcein and propidium iodide (PI) staining for live and dead cells,
respectively (Scale bars: 200 μm; ×20 magnification). Data represent the mean ± SEM
of at least 3 independent experiments. *P<0.05 vs vehicle control by Student t test
(A, B, and E).
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Discussion
IH is a unique tumor model, characterized by a rapid proliferative phase followed
by a spontaneous or propranolol-induced involution phase. The mechanisms that
trigger spontaneous involution and the action of propranolol are still under investigation.
The present study shows that the reprogramming factor LIN28B is highly expressed in
the proliferative IH phase but is significantly decreased in involuted IH and in IH tissues
from propranolol-treated patients. The high LIN28B expression in proliferative IH
correlates with the expression of the ESC-enriched mir-498(46)99, 101, 102 and is inversely
correlated with the expression of let-7 miRNAs. Treatment of iPSCs with propranolol
reduced the expression of LIN28B and mir-498(46) and induced the expression of let-7
family of miRNAs and EMT genes. Moreover, propranolol treatment reduced iPSC cell
proliferation.
The increase in LIN28B and reduction in let-7 reported in this study highlight the
role of stem cells in the pathology of IH. Although HemSCs, which are 0.2% of the
proliferative hemangioma cell population, are believed to be the cellular origin of IH, our
data show that these cells do not express LIN28B and miR-498(46) in tissue culture 204,
320

. However, our in vivo data show that LIN28B is localized in GLUT1 positive

endothelial cells that were previously characterized as stem cell-like320. These cells
formed colonies that could be induced to re-differentiate into endothelial cells,
pericytes/smooth muscle cells or adipocytes. Interestingly, when these GLUT1 positive
endothelial cells were cultured for 3 weeks they converted to a mesenchymal phenotype
and lost GLUT1 and mir-498(46) expression 119, 320. It would be of interest to test
whether freshly isolated HemSCs express LIN28B and mir-498(46) or implantation of
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HemSC into immunodeficient mice restores LIN28B and mir-498(46) expression.
Nevertheless, increased expression of stem cell transcription factors OCT4, SOX2,
NANOG and MYC have been reported in IH 318. In addition, our in vivo data also show
that in proliferative IH LIN28 was not limited to GLUT1 positive cells but was also
expressed in perivascular non-endothelial cells, which are essential for the maintenance
of IH vessels stability322.
The increase in LIN28B in IH reported here may be due to transcriptional and/or
post transcriptional activation. The reprogramming transcription factors such as MYC
has been shown to transactivate LIN28B323, 324. Although little is known about the
transcriptional activation of LIN28B, posttranscriptional regulation by miRNAs such as
let-7 and other miRNAs has been extensively studied129, 165. Furthermore, LIN28B was
reported to bind its own mRNA, increasing its stability and protein abundance133. Thus,
our sRNAseq results are in line with previous reports and highlight the central role of the
LIN28B/let-7 switch in governing stem cell self-renewal in the proliferative phase of IH.
We also showed that the ESC-enriched miRNA cluster mir-498(46) is highly
expressed in IH. This cluster of miRNAs is normally imprinted, with only the paternally
inherited allele expressed in the placenta97. The overexpression of mir-498(46) seen in
IH could be regulated by methylation of the upstream CpG island or by chromosomal
rearrangements such as amplifications of the corresponding chromosome 19 region, as
found in embryonal tumor with multilayered rosettes (ETMRs) 16, primitive
neuroectodermal tumors (PNETs) and in thyroid adenomas 118, 122, 325. Given the ability
of IH to undergo spontaneous involution, the elevated expression of mir-498(46) in
proliferative IH is unlikely to be due to DNA amplifications or translocations, but rather,
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due to epigenetic modification. We therefore proceeded to investigate the previously
identified promoter region and transcription start site that overlap an annotated CpG
island located ~17 kb upstream of the first miRNA gene of mir-498(46). Although our
findings show that, unlike NS, IH samples exhibited active transcription starting from the
upstream CpG island, similar to that seen in the placenta97, they do not preclude the
existence of additional active promoter regions within mir-498(46). In fact, mir-498(46)
carries numerous CpG dinucleotide islands extensively interspersed with Alu-rich
repeats, which account for over 50% of the 100-kb sequence. Numerous studies
showed that Alu methylation is highly dynamic and Alu-rich regions can function as
independent promoters for RNA polymerase II and RNA polymerase III in both
mesenchymal stem cells and cancer stem cells100, 102, 326.
Although LIN28 is a well-established inhibitor of miRNA maturation133, 140, 147, 148,
the present study revealed that overexpression of LIN28B increased the expression of
miR-516b of mir-498(46). This is especially noteworthy given that LIN28B can be used
along with other reprogramming factors to generate pluripotent stem cells enriched with
mir-498(46). In fact, a recent study showed that LIN28A activates gene expression by
binding directly to a consensus DNA sequence at promoter regions and recruiting the
CpG demethylase TET1327. Previous study showed that both mesenchymal stem and
cancer stem cells exhibit disperse expression patterns of miRNAs of the mir-498(46)
cluster rather than a bloc expression regulated by the upstream promoter 102.
Accordingly, our data show that overexpression of LIN28B did not affect the methylation
of the upstream CpG-island or increase the transcription in that region indicating the
existence of downstream promoter regions. LIN28B may bind to the Alu repeats within
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mir-498(46), which may function as independent RNA polymerase II promoters and
activate transcription by recruiting TET1. In fact, analyses of previously published PARCLIP data show that LIN28B binds numerous Alu repeats located in the mir-498(46)133.
This unexpected result points to a potential binding of LIN28B to the CpG-rich Alu
repeats to activate transcription. Moreover, LIN28 is a potent RNA-binding protein that
regulates splicing factor abundance134, and therefore may induce processing of the
transcript of mir-498(46) cistron.
In the last decade, propranolol has become the preferred treatment for morbid
proliferating IH. To date, more than 500 published articles describe the observed
propranolol-induced involution of IH and the various hypotheses regarding its
mechanisms of action. Here we propose a new model through which propranolol
triggers rapid IH involution. We demonstrate that propranolol induces a shift in
LIN28B/let-7 balance to favor cell differentiation and senescence. This model is based
on the data presented here, which show that propranolol reduced the expression of
LIN28B and increased the expression of let-7 in IH samples in vivo and in iPSCs in
vitro. Furthermore, we show that propranolol reduces the proliferation of iPSCs and
initiates the conversion to mesenchymal phenotype as evidenced by the increase in
SERPINE1 and TWIST1 expression, while reducing the expression of miRNAs of the
mir-498(46) cistron. RNAseq and gene set analyses confirmed the downregulation in
E2F targets, G2M checkpoint and mitotic spindle pathways and showed upregulation in
EMT, adipogenesis, and TGF-β signaling pathways. To our knowledge, this is the first
report to show that propranolol reduces the proliferation of iPSCs and induces EMT and
adipogenesis. These profound effects of propranolol may be due in part to the reduction
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in LIN28B that binds and regulates mRNAs of cell cycle regulators133 and/or as a
consequence of the increase in let-7 miRNAs, which regulate Rb1/E2F genes328. The
induction of EMT genes by propranolol is in agreement with a previous study that
showed that activation of adenylyl cyclase and elevation in cAMP and EPAC signaling
replaced the need for OCT4 for iPSC generation. This cAMP-dependent reprograming
increased cellular division rate and induced genes involved in MET329. Therefore, by
reducing cAMP levels, propranolol may be inducing EMT and thus accelerating IH
involution. Of note, propranolol has been shown to induce adipogenesis in hemangioma
stem cells330, 331. Lastly, the reduction in miRNAs of the mir-498(46) cistron in
propranolol treated iPSCs reported here is in agreement with previous work that
showed that propranolol treated IH tissues contained significantly lower levels of mir498(46) miRNAs than did proliferative, untreated IH119.
The LIN28/let-7 axis is implicated not only in pluripotency but also in
tumorigenesis, especially in cancer stem cells, which are resistant to chemotherapies
and promote metastasis129, 332. In fact, numerous pre-clinical and clinical studies provide
evidence that propranolol increases chemosensitivity and reduces the metastatic rates
in multiple cancer types333. The present work highlights the role of the LIN28B/let-7
switch in IH pathogenesis and propranolol induced IH involution. This study may also
have therapeutic implications for IH and for cancers in which the LIN28/let-7 pathway is
imbalanced.
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Chapter 8
Limitations and Overall Conclusions
Limitations
To study the role of C19MC in trophoblast differentiation, we employed a
CRISPR/SAM based method that utilizes guide RNAs targeted to a region directly
upstream of the first C19MC miRNA. Although transient transfection of CRISPR/SAM
components in HEK293 cells induced robust C19MC expression and yielded valuable
data, it is not sufficient to study the long-term effects of C19MC overexpression. Further
studies using stable lentiviral vectors will be necessary to determine the long-term
effects of C19MC overexpression. Furthermore, transient and stable C19MC
knockdown experiments are required to provide definite proof that C19MC regulates
EMT. Due to its large size, we have been unable to successfully knockdown its
expression.
Another potential limitation to this study is the use of a low dose BMP treatment
protocol for the differentiation of iPSCs to iPSC-CTs. Our data shows that C19MC
miRNAs are decreased and EMT makers are increased upon iPSC differentiation to
CTs. Although this data further strengthens the hypothesis that the EMT process is
associated with a decrease in C19MC miRNA expression, use of a differentiation
protocol which does not itself induce EMT would further clarify the role of C19MC.
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To test the effect of propranolol on C19MC miRNAs and the LIN28B/let 7
signaling pathway, we used iPSCs which express high levels of C19MC and LIN28.
However, GLUT1 positive hemangioma endothelial cells isolated from proliferative IH
would have been the ideal cells to use in these studies as they are directly relevant to
the pathophysiology of IH. These cells have also been characterized as stem like.
Unfortunately, although the hemangioma endothelial cells express GLUT1 and C19MC
when freshly isolated, they have been shown to convert to a mesenchymal phenotype
and lose GLUT1 and C19MC expression after 3 weeks in culture. In addition to the
culturing constraints which have the ability to confound our study, we did not have
access to these cells. We therefore used iPSCs which allowed us the opportunity to
generate data that have implications beyond IH. Another limitation to our study is the
limited access to propranolol treated and involuted IH tissues. Since propranolol causes
a rapid involution, surgical intervention is not needed. Thus, we could not directly
compare the expression of C19MC and EMT markers in proliferative and propranolol
treated IH. Measuring changes in EMT markers in propranolol treated IH could
potentially add translational relevance to our study.

Overall conclusions
In this study, we sought to determine the role of C19MC in placental trophoblast
differentiation. First, we show in situ that C19MC is highly expressed in VTs but not in
the invasive EVTs and decidua of first trimester human placentas. To test the effect of
C19MC miRNAs, we designed a new method to transcriptionally activate the entire
C19MC cistron. Using this highly efficient method, we showed that overexpression of

120

C19MC in HEK293 cells decreased the expression of EMT markers and increased the
expression of stemness genes OCT4 and FGF4. This indicates that these miRNAs play
a role in the maintenance of the epithelial phenotype and stemness in stem cells and
VTs. Hallmark gene set analysis also showed that C19MC targets many mRNAs
involved in cell differentiation pathways including EMT and Hedgehog signaling
pathways.
Since the early placental environment is hypoxic, we tested the effect of hypoxia
on C19MC miRNA expression in vitro. Our results show that hypoxia decreases C19MC
and increases EMT gene expression. Although the mechanism by which hypoxia
decreases the expression of C19MC miRNAs is unknown, the data suggests that
hypoxia facilitates trophoblast differentiation during early pregnancy by decreasing
C19MC thus promoting EMT. In addition, co-expression of C19MC miRNAs along with
Yamanaka factors resulted in a significant increase in number of stem cell colonies and
overall efficiency of reprogramming. This is likely due to an increase in expression of the
pluripotency factor OCT4 and FGF4 induced by C19MC overexpression. Taken
together, this study establishes the utility of the CRISPR/SAM technique as a tool to
investigate the role of C19MC in placental physiology. This study also establishes the
important role of C19MC in the maintenance of stemness and shows that loss of
C19MC miRNAs is essential for EMT and trophoblasts and stem cells differentiation.
Since trophoblast migration and invasion is extremely important for optimal placentation
and fetal growth, dysregulation of C19MC can have detrimental effects during
pregnancy.
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We also investigated the roles of C19MC and LIN28 in IH. we presented
evidence that LIN28B is the paralog that is highly expressed in IH. We also show in
human tissue sections, that LIN28B is highly expressed in proliferating IH but is reduced
in involuting IH and propranolol treated IH tissues. We also show that the high Lin28
expression in proliferative IH is accompanied by a decrease in let 7 miRNA expression
consistent with the evolutionarily conserved negative feedback loop described in the
literature. Furthermore, overexpression of LIN28B in HEK293 cells was sufficient to
induce the expression of miR-516b, a C19MC miRNA without altering the methylation
status of the CpG island upstream of C19MC or increase transcription in the region.
These data indicate that LIN28B increase miRNAs of the c19MC in a methylation
independent mechanism. This study also shows that propranolol has a profound effect
on C19MC and LIN28B expression. iPSCs treated with propranolol showed a marked
decrease in the expression of C19MC and LIN28B and an increase in EMT markers.
These results demonstrate that propranolol induces IH involution by decreasing the
expression of C19MC, inducing EMT, and altering the balance of the Lin28B/let-7
signaling pathway.
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